antibody-conjugated nanoparticles
Patent Information
- Application Number
- JP2023528130
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-06
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for gene editing in hematopoietic stem cells (HSCs) face challenges such as cytotoxicity, inefficiency in cell delivery, and the lack of suitable delivery systems, particularly for in vivo applications, due to the absence of unique HSC cell surface markers and the sensitivity of HSCs to conventional gene targeting procedures.
Development of antibody conjugate nanoparticles, specifically targeting HSCs using high-affinity antibodies against CD34 and Gpr56, conjugated to biodegradable PLGA nanoparticles to deliver a gene editing payload, enhancing specificity and reducing cytotoxicity.
The antibody-conjugated nanoparticles effectively target and deliver gene editing payloads to HSCs, improving the efficacy-toxicity ratio and enabling efficient gene editing with reduced cytotoxicity, suitable for both ex vivo and in vivo applications.
Smart Images

Figure 00000063_0000 
Figure 00000063_0001 
Figure 00000063_0002
Abstract
Description
Background Art
[0001] Blood malignancies and non-tumorigenic genetic diseases such as, for example, sickle cell disease (SCD) and β-thalassemia are caused by mutations that affect the proper function of the hematopoietic system. With the increase in average life expectancy, the number of elderly individuals diagnosed with hematological conditions has increased significantly. Considering the dynamic nature and genetic heterogeneity of the hematopoietic system among disorders and patients, the treatment and prevention of blood disorders remain challenging. Hematopoietic stem cells (HSCs) offer a great opportunity to develop novel treatments for a number of malignant and non-malignant diseases. The ability to self-renew and differentiate into all blood lineages has already been utilized in stem cell therapy. Novel treatments such as gene editing aim to manipulate autologous HSCs to regress disease symptoms. In other situations, it may be necessary to remove diseased / depleted HSCs (e.g., those in the process of aging), block receptors of hematopoietic stem and progenitor cells (HSPCs) (e.g., of acute myeloid leukemia), or in HSC transplantation, recipient HSCs need to be specifically removed with cytotoxic drugs while non-hematopoietic cells (e.g., during bone marrow transplantation) are not affected.
[0002] In the case of gene editing, allogeneic or autologous HSCs are manipulated ex vivo and the edited HSCs are reinjected into the patient. However, this has several drawbacks: (1) the risk of cell differentiation and loss of the potential for homing / engraftment of purified target cells; (2) the lack of accurate markers to enable isolation of sufficient long-term repopulating HSCs; (3) the pre-transplant conditioning used to "make space" for engraftment of isolated and reinjected HSCs has severe acute toxicity to multiple organs, which is a limitation in the treatment of elderly patients; (4) ex vivo gene editing of HSCs requires specialized medical centers and only a very small number of patients have access, especially patients in underdeveloped regions of the world are excluded.
[0003] Efficient gene editing in HSPCs has been achieved by delivering CRISPR using electroporation and / or viral transduction, but cytotoxicity is a drawback of currently used methods. Nanoparticle (NP)-based gene editing strategies could further enhance the potential of gene editing in HSPCs and provide a delivery system for in vivo application.
[0004] However, a bottleneck in the development of HSC-targeted therapies is the lack of a suitable and specific HSC delivery system.
[0005] One limitation in the development of HSC-targeted therapies is the lack of unique HSC cell surface markers. For example, CD34 is commonly used to isolate HSCs from blood and bone marrow, but it represents a heterogeneous cell population including immune cells and endothelial cells. Recently, the G protein-coupled receptor gpr56 has been described as a novel marker expressed in HSCs, and it has been shown that all mouse long-term regrowing HSCs express gpr56.
[0006] In vivo targeting of known HSC cell surface receptors can be significantly improved by enhancing the endocytotic capacity of HSPCs using conventional high-affinity antibodies (H2L2 Abs). The possibility of modifying bispecificity Abs means that newly developed human heavy-chain-only antibodies or their VH region alone may also improve targeting of HSCs. Both types of antibodies have the additional advantage of being human, thus avoiding immune responses.
[0007] Many therapeutic compounds and gene-editing components are easily degraded and have low potential membrane permeability. A highly non-toxic delivery system will be required for in vivo delivery to HSCs. Nanoparticles (NPs) made from biodegradable and FDA-approved PLGA protect the payload from premature degradation and guide the payload to target cells. High-level payload delivery with PLGA-NPs improves the efficacy / toxicity ratio; this is highly desirable for HSCs sensitive to the cytotoxicity of conventional gene-targeting procedures.
[0008] [Overview of the project]
[0009] The present invention provides an antibody conjugate comprising an antibody and nanoparticles conjugated to the antibody, wherein the nanoparticles contain a gene editing payload.
[0010] The present invention further provides an ex vivo method for gene editing, comprising administering an antibody conjugate containing a gene editing payload to a cell population including cells expressing a surface antigen to which an antibody specifically binds.
[0011] The present invention further provides a method for treating a disease, comprising administering an antibody conjugate containing a gene editing payload to a patient.
[0012] The present invention further provides an antibody conjugate comprising an anti-CD34 antibody and nanoparticles conjugated to the antibody, wherein the nanoparticles comprise a payload. Furthermore, the present invention provides an antibody conjugate comprising an anti-Gpr56 antibody and nanoparticles conjugated to the antibody, wherein the nanoparticles comprise a payload.
[0013] Methods for producing antibody conjugates are also provided herein, comprising: modifying an antibody heavy chain coding sequence to introduce a cysteine residue at or near the C-terminus of the heavy chain constant region; generating a modified antibody from the modified sequence (the modified antibody contains a cysteine residue at or near the C-terminus of the heavy chain constant region, and the cysteine residue has a free thiol group that is not covalently bonded to another cysteine residue); obtaining PEG-containing poly(lactic acid-coglycolic acid) (PLGA) nanoparticles; and conjugating the nanoparticles to the antibody via site-directed maleimide bonding (the cysteine residue at or near the C-terminus of the heavy chain constant region is covalently bonded to one or more PEG groups of the nanoparticles).
[0014] The present invention further provides a method for treating or improving symptoms of a hereditary disorder, comprising administering a composition comprising an antibody conjugate to a patient, wherein the antibody conjugate comprises an antibody and nanoparticles conjugated to the antibody, and the nanoparticles comprise a gene editing payload. Furthermore, the present invention provides an antibody conjugate for use in treating or improving symptoms of a hereditary disorder, comprising an antibody and nanoparticles conjugated to the antibody, wherein the nanoparticles comprise a gene editing payload.
[0015] The present invention provides a method for treating or improving the symptoms of a disease, comprising administering a composition comprising an antibody conjugate to a patient, wherein the antibody conjugate comprises an anti-Gpr56 antibody and nanoparticles conjugated to the antibody, and the nanoparticles comprise a therapeutic payload. Furthermore, the present invention provides an antibody conjugate for use in treating or improving the symptoms of a disease, comprising an anti-Gpr56 antibody and nanoparticles conjugated to the antibody, wherein the nanoparticles comprise a therapeutic payload.
[0016] The present invention also provides a method for treating or improving the symptoms of a disease, comprising administering a composition comprising an antibody conjugate to a patient, wherein the antibody conjugate comprises an anti-CD34 antibody and nanoparticles conjugated to the antibody, and the nanoparticles comprise a therapeutic payload. Furthermore, the present invention provides an antibody conjugate for use in treating or improving the symptoms of a disease, comprising an anti-CD34 antibody and nanoparticles conjugated to the antibody, wherein the nanoparticles comprise a therapeutic payload.
[0017] The present invention further provides an anti-CD34 antibody comprising a heavy chain variable region (VH) containing three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) containing three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 containing the amino acid sequence of SEQ ID NO: 1; HCDR2 containing the amino acid sequence of SEQ ID NO: 2; and HCDR3 containing the amino acid sequence of SEQ ID NO: 3; and VL comprises LCDR1 containing the amino acid sequence of SEQ ID NO: 4; LCDR2 containing the amino acid sequence of SEQ ID NO: 5; and LCDR3 containing the amino acid sequence of SEQ ID NO: 6.
[0018] The present invention also provides an anti-Gpr56 antibody comprising a heavy chain variable region (VH) containing three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) containing three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 containing the amino acid sequence of SEQ ID NO: 9; HCDR2 containing the amino acid sequence of SEQ ID NO: 10; and HCDR3 containing the amino acid sequence of SEQ ID NO: 11; and VL comprises LCDR1 containing the amino acid sequence of SEQ ID NO: 12; LCDR2 containing the amino acid sequence of SEQ ID NO: 13; and LCDR3 containing the amino acid sequence of SEQ ID NO: 14. [Brief explanation of the drawing]
[0019] [Figure 1A] Expression patterns of CD34 and gpr56 in umbilical cord blood and peripheral blood. Flow cytometry dot plots showing gating and proportion of CD34+, Gpr56+, and CD34+gpr56+ cells in umbilical cord blood (left) and peripheral blood (PBMC, right). Viable blood cells were gated based on FSC-A and SSC-A (no cell fragments), and then 7-AAD+ cells (dead cells) were excluded. Viable cells were further analyzed for CD34 (CD34-PE-Cy7, commercially available antibody) and gpr56 (gpr56-PE, commercially available antibody) expression. [Figure 1B]Expression patterns of CD34 and gpr56 in umbilical cord blood and peripheral blood. PBMC gating strategy based on CD34 / gpr56 dual labeling. CD34+gpr56-, CD34+gpr56+, and CD34-gpr56+ cells were sorted and plated on methylcellulose. [Figure 1C] Expression patterns of CD34 and gpr56 in umbilical cord blood and peripheral blood. Hematopoietic capacity correlates with gpr56 expression. Number of hematopoietic progenitor cells in umbilical cord blood CD34+, gpr56+, CD34+gpr56-, CD34+gpr56+, and CD34-gpr56+ selected cells. CFU-C (culture colony-forming units) per 700 selected cells are shown, and the colony type is indicated by a colored bar: CFU-G = granulocyte CFU, CFU-M = macrophage, and CFU-GM = granulocyte-macrophage CFU, CFU-GEMM = granulocyte-erythrocyte-megakaryocyte-macrophage CFU, and BFU-E = erythrocyte burst-forming unit. [Figure 2A] Novel fully human α-gpr56 and α-CD34 antibodies were generated. A schematic diagram of the fully human antibody generation process is shown. The extracellular domains of human gpr56 and CD34 were expressed as his-tagged fusion proteins in HEK293 cells (not shown) and used for immunization of H2L2 transgenic mice (Harbour). Subsequently, hybridomas were generated and antigen-binding antibodies were cloned. [Figure 2B] Generating novel fully human α-gpr56 and α-CD34 antibodies. Schematic diagram of selected mAbs. Two clones exhibiting high affinity for human gpr56 (clone 3.8g8) and CD34 (L5F1) were selected to generate fully human α-gpr56 and α-CD34 antibodies. From each clone, a standard antibody format and a format containing two extra cysteine groups in the Fc region were generated. [Figure 2C]Generation of novel fully human α-gpr56 and α-CD34 antibodies. The fully human α-gpr56 (clone 3.8g8) and α-CD34 (L5F1) antibodies (without extra cysteine) were directly conjugated to Atto-647-NHS-ester at a labeling degree of 2 dyes / molecule antibody. Cord blood was labeled with α-CD34-PE-Cy7 and α-gpr56-PE commercial mAb) antibodies, or α-gpr56-Atto647 (clone 3.8g8) and α-CD34-Atto647 (clone L5F1). [Figure 3A] Conjugation strategy of antibodies to PLGA-PEG-NPs. Schematic of a fully human H2L2 antibody incorporating two extra cysteines with free thiol groups in the Fc region. [Figure 3B] Conjugation strategy of antibodies to PLGA-PEG-NPs. Schematic of PLGA-PEG-NPs. (Left) Conjugation using NHS-ester randomly crosslinks the antibody to the PLGA-PEG(-NH2)-NP surface via any lysine present in the antibody sequence. (Right) Conjugation via maleimide-cysteine is specific to the free cysteine in the Fc tail. All other cysteines present in the antibody sequence are involved in disulfide bridging with adjacent cysteines. This site-specific conjugation strategy ensures proper orientation of all antibody variable regions (and antigen-binding grooves) away from the NP core. [Figure 3C] Conjugation strategy of antibodies to PLGA-PEG-NPs. Representative TEM image of CD34-PLGA-PEG-NPs. The scale bar is shown. [Figure 3D] Conjugation strategy of antibodies to PLGA-PEG-NPs. Representative confocal images of empty PLGA-PEG-NPs and CD34-PLGA-PEG-NPs. Red = anti-human Fc-AF488. The scale bar is shown. [Figure 4A]α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in the blood. Flow cytometry dot plots showing gating of CD34− and CD34+ cells in peripheral blood mononuclear cells (PBMCs). [Figure 4B] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in the blood. Representative analysis of viable CD34+ and viable CD34− populations incubated with α-CD34-PLGA-PEG-NP. PBMCs were incubated with 20 μg / ml of α-CD34(Cys)-PLGA-PEG-NP conjugated via NHS ester and maleimide thiol for 15 minutes, washed thoroughly, and analyzed by flow cytometry. Viable blood cells (7-AAD−) were gated as CD34+ and CD34− cells, and subpopulations were further analyzed for the expression of DiD, a fluorophore encapsulated inside the PLGA-PEG-NP. [Figure 4C] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in the blood. Binding of (conjugated via NHS-ester reaction or maleimide-thiol reaction to α-gpr56(Cys), α-CD34(Cys), α-MSLN(Cys), and α-Strep) NPs to CD34+ and CD34− blood cells was evaluated. The percentages of CD34+ and CD34− cells bound to the fluorescent carrier were determined by flow cytometry. Data represent mean ± SEM of 4 - 7 independent experiments including at least 3 different donors. Two-way ANOVA and Bonferroni's multiple comparison test were used to calculate statistical significance. αgpr56- and αCD34-NPs were compared to αMSLN-NP and αStrep-NP. *=0.0154, **=0.0099, ***=0.0002, ****<0.0001. [Figure 4D]α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in blood. To determine the specificity of NP binding, experiments were conducted with and without pre-blocking of FcR on PBMCs, and the PBMCs were then incubated with different NP batches at 37°C for 15 minutes. Data represent the mean ± SEM of 2–4 independent experiments involving at least two different donors. Statistical significance was calculated using two-way ANOVA and Bonferroni's multiple comparison test. Fc-blocked samples were compared to their unblocked counterparts. [Figure 4E] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in the blood. (E) Binding dynamics of NPs conjugated to α-gpr56(Cys), α-CD34(Cys), or α-MSLN(Cys) mAbs, conjugated by the NHS-ester reaction and (F) the maleimide-thiol reaction with CD34+PBMCs over time (0-120 mins). The percentage of CD34+ cells internalizing the fluorescent carrier was measured by flow cytometry. Data represent the mean ± SEM of two independent experiments using one donor. Statistical significance was calculated using two-way ANOVA and Bonferroni's multiple comparison test. α-gpr56- and α-CD34-NP were compared with α-MSLN-NP at each time point. **=0.006, ***=0.0005, ****=<0.0001. [Figure 4F]α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in the blood. (E) Binding dynamics of NPs conjugated to α-gpr56(Cys), α-CD34(Cys), or α-MSLN(Cys) mAbs, conjugated by the NHS-ester reaction and (F) the maleimide-thiol reaction with CD34+PBMCs over time (0-120 mins). The percentage of CD34+ cells internalizing the fluorescent carrier was measured by flow cytometry. Data represent the mean ± SEM of two independent experiments using one donor. Statistical significance was calculated using two-way ANOVA and Bonferroni's multiple comparison test. α-gpr56- and α-CD34-NP were compared with α-MSLN-NP at each time point. **=0.006, ***=0.0005, ****=<0.0001. [Figure 4G] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in the blood. Binding and uptake of NPs conjugated to α-gpr56(Cys), α-CD34(Cys), α-MSLN(Cys), or α-Strep(Cys), conjugated at 4°C (binding) or 37°C (binding and uptake) for 1 hour, were observed via the maleimide-thiol reaction with CD34+PBMC. Data represent the mean ± SEM of two independent experiments involving two donors. Statistical significance was calculated using two-way ANOVA and Bonferroni's multiple comparison test. α-gpr56-, αCD34-NP, and αMSLN were compared, respectively. [Figure 4H]α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target HSPCs in blood. NPs coated with α-gpr56(Cys), α-CD34(Cys), α-MSLN(Cys), or α-Strep(Cys) are conjugated by a maleimide-thiol reaction with isolated CD34+ blood cells (derived from PBMCs). CD34+ cells were isolated from PBMCs using CD34+ magnetic beads and subsequently incubated with 10 (different NP batches of μg / ml). The percentage of CD34+ cells bound to the fluorescent carrier was determined by flow cytometry. [Figure 5A] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP are internalized in HSPCs. (A) Human PBMCs, or (B) Isolated CD34+ cells (from PBMCs) were incubated for 1 hour with NPs coated with α-gpr56(Cys) (top image), α-CD34(Cys) (middle image), and α-MSLN(Cys) (bottom image) (conjugated by maleimide-thiol reaction), washed, then seeded for 15 minutes on poly-L-lysine coated coverslips, fixed, and stained with CD34 (green) and DAPI (blue). Encapsulated DiD (red). Cells were analyzed using a Leica SP5 confocal laser scanning microscope with a 63x oil objective lens. Images represent the intermediate focal plane. Scale bar = 10 μm. [Figure 5B]α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP are internalized in HSPCs. (A) Human PBMCs, or (B) Isolated CD34+ cells (from PBMCs) were incubated for 1 hour with NPs coated with α-gpr56(Cys) (top image), α-CD34(Cys) (middle image), and α-MSLN(Cys) (bottom image) (conjugated by maleimide-thiol reaction), washed, then seeded for 15 minutes on poly-L-lysine coated coverslips, fixed, and stained with CD34 (green) and DAPI (blue). Encapsulated DiD (red). Cells were analyzed using a Leica SP5 confocal laser scanning microscope with a 63x oil objective lens. Images represent the intermediate focal plane. Scale bar = 10 μm. [Figure 6A] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target different hematopoietic progenitor cell populations in the blood. Flow cytometry dot plots showing gating and proportion of HSPC populations in peripheral blood. NP uptake selectivity was determined within different HSPC subpopulations. PBMCs were incubated with 20 μg / ml of α-gpr56(Cys)-PLGA-PEG-NP, α-CD34(Cys)-PLGA-PEG-NP, and α-Strep(Cys)-PLGA-PEG-NP (maleimide) at 37°C for 15 minutes, followed by staining with a panel of flow cytometry markers. (Above) CD34+ cells were gated using a sequential Boolean gating strategy in accordance with the Clinical Laboratory Standards Institute (CLSI) H42-A2 approved guidelines, combining CD34, CD45, SSC, and FSC parameters. Dead cells were excluded by 7-AAD positive staining. Monocytes and lymphocytes could be gated based on morphology within the CD45V population. (Central) Surviving CD34+ cells (CD34V) were further gated to the CD34+CD38- population. Next, the CD34+CD38- events were further subdivided into a pluripotent progenitor cell (MPP) population characterized as CD34+CD38-CD90-CD45RA- and a HSC population characterized as CD34+CD38-CD90+CD45RA-. [Figure 6B] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target different hematopoietic progenitor cell populations in the blood. Surviving CD34+ cells that were subjected to CD38+CD10+ events were the common lymphoid progenitor cells (CLPs). The CD38+CD10- population included myeloid common progenitor cells (CMP, CD34+CD38+CD135+CD45RA-), granulocyte-macrophage progenitor cells (GMP, CD34+CD38+CD135+CD45RA+), and megakaryocyte-erythrocyte progenitor cells (MEP, CD34+CD38+CD135-CD45RA-). [Figure 6C] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target different hematopoietic progenitor cell populations in the blood. Summary of flow cytometry analysis of DiD+ PBMC subsets. The proportion of DiD+ cells was analyzed in different PBMC subpopulations as gated in A. [Figure 6D] α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP specifically target different hematopoietic progenitor cell populations in the blood. The data in Panel C represent the mean ± SEM of 4–7 independent experiments involving at least three different donors. [Figure 7A] Selection of high-affinity clones. Screening of αCD34 high-affinity clones by flow cytometry. Examples of clones tested. Jurkat cells were incubated with 10 μg / ml primary antibody (rat isotype) and then labeled with α-ratAF647 secondary antibody. [Figure 7B] Selection of high-affinity clones. Screening of αGpr56 high-affinity clones by flow cytometry. Examples of clones tested. 32D-Gpr56 cells were incubated with 10 μg / ml primary antibody (rat isotype) and then labeled with α-ratAF647 secondary antibody. [Figure 8]Confocal schematic images of α-gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP targeting HSPCs within PBMCs. (A) Human PBMCs were incubated for 1 hour with NPs coated with α-gpr56(Cys), α-CD34(Cys), and α-MSLN(Cys) (conjugated via maleimide-thiol), washed, then seeded for 15 minutes on poly-L-lysine coated coverslips, fixed, and stained with CD34 (green) and DAPI (blue). Encapsulated DiD (red). Cells were analyzed using a Leica SP5 confocal laser scanning microscope with a 63x oil objective lens. Images represent the intermediate focal plane. Scale bar = 100 μm. [Figure 9] Overview of CD34 antibodies. The upper panel shows the affinity of various anti-CD34 antibodies. The lower panel shows the heavy and light chain sequences of anti-CD34 antibodies. The red arrow indicates the sequence of the anti-CD34 antibody L5F1 used in the targeting experiment. [Figure 10] Gpr56 antibody sequences. The heavy and light chain sequences of many anti-Gpr56 antibodies are shown. The red arrow indicates the antibody sequence of anti-Gpr56 antibody 3.8g8 used in the targeting experiment. [Figure 11A] Characterization of CRISPR / Cas9-PLGA-NPs. Schematic diagram of CRISPR / Cas9 nanoparticles (NPs) made from polylactic acid-coglycolic acid (PLGA). The CRISPR component was encapsulated in the form of a single guide RNA (sgRNA) and purified Cas9 (S. pyogenes) protein. In addition, the NPs were equipped with a fluorescent dye (acidic Cy5). [Figure 11B] Characterization of CRISPR / Cas9-PLGA-NP. Schematic diagram of the CRISPR / Cas9-PLGA-NP synthesis protocol using the double emulsion solvent evaporation method. [Figure 11C] Characterization of CRISPR / Cas9-PLGA-NP. Representative transmission electron microscope images of CRISPR / Cas9-PLGA-NP formulations. Scale bar = 2 μm. [Figure 11D]Characterization of CRISPR / Cas9-PLGA-NPs. Representative dynamic light scattering measurements of CRISPR / Cas9-PLGA-NP formulations. The average size of the NPs was 350-400 nm in diameter. [Figure 11E] Characterization of CRISPR / Cas9-PLGA-NPs. The release dynamics of Cas9 from (E) Atto-550 labeled gRNA and (F) CRISPR / Cas9-PLGA-NPs in PBS at pH 7.4 and 37°C were studied. The inset shows the dynamic release curve for the first 24 hours. At specified time points, the release medium was collected, and the levels of gRNA and Cas9 were quantified by spectrophotometer and nanodrop measurement, respectively. The results show a representative release rate curve. [Figure 11F] Characterization of CRISPR / Cas9-PLGA-NPs. The release dynamics of Cas9 from (E) Atto-550 labeled gRNA and (F) CRISPR / Cas9-PLGA-NPs in PBS at pH 7.4 and 37°C were studied. The inset shows the dynamic release curve for the first 24 hours. At specified time points, the release medium was collected, and the levels of gRNA and Cas9 were quantified by spectrophotometer and nanodrop measurement, respectively. The results show a representative release rate curve. [Figure 12A] Upregulation of HbF in primary human erythroblasts. Human PBMCs were differentiated into erythroblasts and treated with CRISPR / Cas9-PLGA-NP or control NP on day 8 (start of phase 2). The upper panel shows representative flow cytometry plots of primary erythroblasts 3 days after treatment with 50 μg / ml or 200 μg / ml CRISPR / Cas9-PLGA-NP
[21] , or control NP encapsulating a scrambled sgRNA sequence at 200 μg / ml. The lower panel shows the percentage of NP+ (Cy5+) cells. [Figure 12B] Upregulation of HbF in primary human erythroblasts. Human PBMCs were differentiated into erythroblasts and treated with CRISPR / Cas9-PLGA-NP or control NP on day 8 (start of phase 2). Percentage of β-globin mRNA relative to the total level of β-globin + γ-globin (%). [Figure 12C]Upregulation of HbF in primary human erythroblasts. Human PBMCs were differentiated into erythroblasts and treated with CRISPR / Cas9-PLGA-NP or control NP on day 8 (start of phase 2). Percentage of HbF+ cells (%) at days 3, 8, and 14 after treatment with 50, 100, or 200 μg / ml CRISPR / Cas9-PLGA-NP or 200 μg / ml control NP. [Figure 12D] Upregulation of HbF in primary human erythroblasts. Human PBMCs were differentiated into erythroblasts and treated with CRISPR / Cas9-PLGA-NP or control NP on day 8 (start of phase 2). Top: Portrait of the HBB locus on chromosome 11. Section of the HBG1 promoter region showing spacers (purple) and protospacer-adjacent motifs (pink) to identify sgRNA binding and Cas9 cleavage sites. gRNA is complementary to the antisense strand. Green nucleotides indicate BCL11A binding sites. Arrows indicate predicted Cas9 cleavage sites. Bottom: Sanger sequencing trace data from primary erythroblasts 14 days after treatment with 200 μg / ml CRISPR / Cas9-PLGA-NP or control NP. [Figure 12E] Upregulation of HbF in primary human erythroblasts. Human PBMCs were differentiated into erythroblasts and treated with CRISPR / Cas9-PLGA-NP or control NP on day 8 (start of phase 2). TIDE analysis of Sanger sequencing data from most erythroblasts edited with CRISPR / Cas9-PLGA-NP. [Figure 13] Cy5 expression in methylcellulose colonies derived from wild-type (WT) or CRISPR / Cas9-PLGA-NP treated human CD34+ cells. Colonies were imaged at 700 nm using an Odyssey scanner on day 14. Cy5 = green. [Figure 14A]NP incorporation and gene editing of the HBG promoter region in primary human CD34+ cells. The top image shows representative photographs of isolated CD34+ cells treated with 100 μg / ml CRISPR / Cas9-PLGA-NP (Cy5, red) at 37°C for 1 hour and analyzed by confocal microscopy. Cells were washed, fixed, and stained with DAPI (nuclei = blue). The bottom image shows cells labeled with the cell surface marker CD34 (green). [Figure 14B] NP uptake and gene editing of the HBG promoter region in primary human CD34+ cells. Binding and uptake of CRISPR / Cas9-PLGA-NP by isolated CD34+ cells at 4°C (binding) or 37°C (binding and uptake) for 1 hour. Data represent the mean ± SEM of two independent experiments including one donor. [Figure 14C] NP incorporation and gene editing of the HBG promoter region in primary human CD34+ cells. Representative flow cytometry plot of CD34+ cells treated with 200 μg / ml CRISPR / Cas9-PLGA-NP at 37°C for 30 minutes. [Figure 14D] NP incorporation and gene editing of the HBG promoter region in primary human CD34+ cells. Representative images of colonies grown from CD34+ WT cells or CD34+ cells treated with CRISPR / Cas9-PLGA-NP, imaged by fluorescence microscopy. NP (green), scale bar = 100 μm. [Figure 14E] NP incorporation and gene editing of the HBG promoter region in primary human CD34+ cells. Number of hematopoietic progenitor cells in isolated CD34+ cells treated with WT, CRISPR / Cas9-PLGA-NP, or control NP. CFU-C (culture colony-forming units) per 500 sorted cells are shown, and the colony type is indicated by a colored bar: CFU-G = granulocyte CFU, CFU-M = macrophage, and CFU-GM = granulocyte-macrophage CFU, CFU-GEMM = granulocyte-erythrocyte-megakaryocyte-macrophage CFU, and BFU-E = erythrocyte burst-forming unit. [Figure 14F]NP incorporation and gene editing of the HBG promoter region in primary human CD34+ cells. Example of TIDE analysis of BFU-E colonies edited with CRISPR / Cas9-PLGA-NP. [Figure 14G] NP incorporation and gene editing of the HBG promoter region in primary human CD34+ cells. (G) TIDE and (H) WT BFU-E colonies, or colonies edited with CRISPR / Cas9-PLGA-NP or control NP, were analyzed for γ-globin / β-globin mRNA. As a positive control, RNP complexes were delivered to CD34+ cells by electroporation. Data represent the mean ± SEM of five independent experiments. All P-values were compared to their respective control cells using the Mann-Whitney U test. **= <p 0.0065、****=<p 0.001。 [Figure 14H] NP incorporation and gene editing of the HBG promoter region in primary human CD34+ cells. (G) TIDE and (H) WT BFU-E colonies, or colonies edited with CRISPR / Cas9-PLGA-NP or control NP, were analyzed for γ-globin / β-globin mRNA. As a positive control, RNP complexes were delivered to CD34+ cells by electroporation. Data represent the mean ± SEM of five independent experiments. All P-values were compared to their respective control cells using the Mann-Whitney U test. **= <p 0.0065、****=<p 0.001。
[0020] [Modes for carrying out the invention]
[0021] Antibody-conjugated nanoparticles are provided herein along with methods for using the antibody-conjugated nanoparticles and preferred therapeutic applications of the antibody-conjugated nanoparticles. The present invention further provides novel antibodies suitable for therapeutic applications, particularly when conjugated to nanoparticles.
[0022] The antibody-conjugated nanoparticles of the present invention include an antibody, such as an anti-CD34 or anti-GPR56 antibody, conjugated to nanoparticles such as PLGA-PEG nanoparticles. The nanoparticles preferably include a payload, such as a therapeutic payload or a gene editing payload.
[0023] <Antibody> In a preferred embodiment, the antibody in the antibody-conjugated nanoparticle is a monoclonal antibody.
[0024] Preferably, the antibody is a human antibody. As used herein, a human antibody is any fully human antibody, i.e., a monoclonal antibody that does not contain sequences derived from a non-human species. Such human antibodies can be obtained from transgenic rodents containing human and non-human (e.g., endogenous rodent) immunoglobulin genes, such as mice. Antibodies derived from such transgenic rodents may be chimeric antibodies containing a human variable region and a rodent constant region. Human antibodies can be derived from chimeric antibodies by using recombinant DNA technology to replace the rodent constant region with a human constant region, thereby providing a fully human antibody having a human variable region and a constant region. Human antibodies can also be obtained from humans, for example, from isolated human B cells.
[0025] In one embodiment, the antibody is a humanized antibody. As used herein, a humanized antibody is an antibody derived from a non-human species that has been modified to increase its similarity to an antibody derived from a human. The humanized antibody may include a human constant region and a chimeric variable region, such as a chimeric human-mouse constant region. In particular, the humanized antibody may include a non-human complementation-determining region (CDR), such as a mouse heavy CDR and a light CDR. The humanized antibody may be obtained in a CDR transplantation process in which a monoclonal mouse antibody is found and the DNA sequence of the antibody's CDR is identified and isolated. Recombinant DNA technology may then be used to replace the CDR sequence of a fully human antibody with a mouse CDR sequence, thereby providing a humanized antibody sequence having the desired mouse CDR. Further modifications may be made to the CDR sequence region to obtain an optimal balance of minimal immunogenicity while maintaining the desired binding and antigen recognition properties.
[0026] Alternatively, the antibody may be a chimeric antibody, such as a chimeric human-mouse antibody containing a human variable region and a mouse constant region. The antibody may also be a completely non-human antibody, such as a completely mouse antibody, a completely rabbit antibody, or a completely rat antibody.
[0027] In one embodiment, the antibody is any non-immunogenic antibody, for example, any antibody that does not interfere with the immune response in humans or does not substantially interfere with the immune response.
[0028] In some embodiments, the antibody may be a full-length antibody containing Fab and Fc regions, for example, the antibody may be an IgG1, IgG2, IgG3, IgG4, IgA, or IgE antibody. The antibody may also be an antibody fragment, such as a Fab fragment. Preferably, the antibody is an IgG1 antibody. In one embodiment, the constant region of the antibody is mutated to reduce or eliminate the effector function(s) of the constant region. In one embodiment, the antibody is an IgG1 antibody containing the Asn297Ala mutation, which eliminates the effector function.
[0029] In one embodiment, the antibody is a heavy-chain-only antibody (HCAb). An HCAb consists of two heavy chains and lacks the two light chains normally present in a tetrameric antibody. Preferably, the HCAb is human or humanized HCAb. Methods for producing such human or humanized HCAb are described, for example, in WO2006 / 008548, WO2007 / 096779, WO2010 / 109165, and WO2014 / 141192. Alternatively, the HCAb may be a camelid HCAb, e.g., a llama HCAb, a camel HCAb, or an alpaca HCAb.
[0030] In recent years, methods for producing heavy-chain-only antibodies in transgenic mammals have been developed (see WO2006 / 008548). Potentially, functional heavy-chain-only antibodies of any class (IgM, IgG, IgD, IgA, or IgE) can be produced from any mammal (including humans) as a result of antigen challenge, from a transgenic mammal (preferably a mouse).
[0031] Heavy chain-only monoclonal antibodies can be recovered from spleen and lymph node B cells using standard hybridoma techniques and standard cloning techniques (WO2006 / 008548, WO2007 / 096779, WO2010 / 109165, WO2014 / 141192), or recovered from B cell mRNA using phage display techniques (Ward et al., (1989) Nature, 341, 544-546). Heavy chain-only monoclonal antibodies can also be directly cloned from antibody-producing cells (e.g., plasma cells or memory B cells) into mammalian cells (WO2010 / 109165; Drabek et al. (2016) Frontiers in Immunology 7:619). Heavy chain-only antibodies derived from camelids or transgenic animals exhibit high affinity. Sequence analysis of expressed heavy chain-only mRNAs, regardless of whether they were produced in camelids or transgenic animals, shows that diversity arises primarily from a combination of VDJ rearrangements and somatic hypermutations, which supports this observation (De Genst et al., (2005) J. Biol. Chem., 280, 14114-14121, and WO2006 / 008548).
[0032] An important and common characteristic of the VH (VHH) region in natural camelids and humans is that, for optimal solubility and binding affinity, each region is V L The key feature is that it binds as a monomer without relying on dimerization with the region. These characteristics have been previously recognized as particularly suitable for the production of blocking agents and tissue penetration agents (see Holliger, P. & Hudson, PJ (2005) Nature Biotechnology 23, 1126-1136 for an overview) or for the generation of polyvalent heavy chain-only antibodies (WO2006 / 008548).
[0033] Recent advances using transgenic rodents have shown that when the human VH region is used as part of an immunoglobulin locus, antibodies targeting only the heavy chain can also be obtained (WO2006 / 008548, WO2007 / 096779, WO2010 / 109165, WO2014 / 141192).
[0034] Due to the antigen-binding specificity of the antibody molecule, the nanoparticles conjugated to the antibody target specific target cells. In one embodiment, the antibody is specific to an antigen expressed by or on the surface of the target cell. In another embodiment, the antibody is specific to an antigen expressed only by or on the surface of the target cell; that is, there are no other cell types that express the antigen to which the antibody is specific.
[0035] In one embodiment, the antibody targets a cell surface antigen, such as a cell surface protein. In one embodiment, the antibody preferably targets a cell surface protein specific to the target cell, for example, a cell that is a therapeutic target. Thereafter, the antibody targets the target cell with nanoparticles, and the payload is preferably delivered exclusively to the target cell. In one embodiment, the target cell may be a tumor cell, such as a cancerous tumor cell, and optionally, the cell surface protein is a growth factor receptor. In one embodiment, the target cell is a stem cell. In one embodiment, the target cell is a progenitor cell. In a preferred embodiment, the target cell is a hematopoietic stem cell. Most preferably, the target cell surface protein is expressed only on the target cell.
[0036] In some embodiments, the antibody targets a cancer cell surface antigen. Accordingly, in some embodiments, an anti-cancer cell surface antigen antibody is provided, conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-cancer cell surface antigen antibody-conjugated nanoparticle is used to treat cancers expressing cancer cell surface antigens.
[0037] In some embodiments, the antibody targets CD33. Accordingly, in some embodiments, an anti-CD33 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD33 antibody-conjugated nanoparticles are used for the treatment of CD33+ myeloid leukemia (e.g., acute myeloid leukemia).
[0038] In some embodiments, the antibody targets CD30. Accordingly, in some embodiments, an anti-CD30 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD30 antibody-conjugated nanoparticles are used to treat CD30+ lymphomas (e.g., Hodgkin lymphoma or anaplastic large cell lymphoma).
[0039] In some embodiments, the antibody targets CD22. Accordingly, in some embodiments, an anti-CD22 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD22 antibody-conjugated nanoparticles are used to treat CD22+ leukemia (e.g., acute lymphoblastic leukemia, e.g., B-cell precursor acute lymphoblastic leukemia).
[0040] In some embodiments, the antibody targets CD79b. Accordingly, in some embodiments, an anti-CD79b antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD79b antibody-conjugated nanoparticles are used to treat CD79b+ lymphoma (e.g., non-Hodgkin lymphoma, e.g., diffuse large B-cell lymphoma).
[0041] In some embodiments, the antibody targets nectin-4. Accordingly, in some embodiments, an anti-nectin-4 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-nectin-4 antibody-conjugated nanoparticles are used for the treatment of nectin-4+ bladder cancer.
[0042] HER2, EGFR, EGFRvIII, cMET, FGFR-2, and FGFR-3 are target antigens associated with driver oncogenes.
[0043] In some embodiments, the antibody targets HER2. Accordingly, in some embodiments, an anti-HER2 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-HER2 antibody-conjugated nanoparticles are used to treat HER2+ solid tumors (e.g., breast cancer, esophageal cancer, or gastric cancer).
[0044] In some embodiments, the antibody targets EGFR. Accordingly, in some embodiments, an anti-EGFR antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-EGFR antibody-conjugated nanoparticles are used to treat EGFR+ solid tumors (e.g., breast cancer such as triple-negative breast cancer, head and neck squamous cell carcinoma, or non-small cell lung cancer).
[0045] In some embodiments, the antibody targets EGFRvIII. Accordingly, in some embodiments, an anti-EGFRvIII antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-EGFRvIII antibody-conjugated nanoparticles are used for the treatment of EGFRvIII+ gliomas (e.g., glioblastoma).
[0046] In some embodiments, the antibody targets cMET. Accordingly, in some embodiments, an anti-cMET antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-cMET+ antibody-conjugated nanoparticles are used for the treatment of cMET+ solid tumors.
[0047] In some embodiments, the antibody targets FGFR2. Accordingly, in some embodiments, an anti-FGFR2 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-FGFR2 antibody-conjugated nanoparticles are used for the treatment of FGFR2+ solid tumors.
[0048] In some embodiments, the antibody targets FGFR3. Accordingly, in some embodiments, an anti-FGFR3 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-FGFR3 antibody-conjugated nanoparticles are used for the treatment of FGFR3+ solid tumors.
[0049] AXL, HER3, CD166, CEACAM5, GPNMB, mesothelin, LIV1A, tissue factor (TF), CD71, CD228, FRα, NaPi2b, Trop-2, PSMA, CD70, STEAP1, P-cadherin, SLITRK6, LAMP1, CA9, GPR20, and CLDN18.2 are antigens that are overexpressed in some cancer cells.
[0050] In some embodiments, the antibody targets AXL. Accordingly, in some embodiments, an anti-AXL antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-AXL antibody-conjugated nanoparticle is used for the treatment of AXL+ solid tumors (e.g., ovarian cancer, cervical cancer, endometrial cancer, non-small cell lung cancer, thyroid cancer, melanoma, or sarcoma).
[0051] In some embodiments, the antibody targets HER3. Accordingly, in some embodiments, an anti-HER3 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-HER3 antibody-conjugated nanoparticles are used for the treatment of HER3+ solid tumors (e.g., breast cancer or non-small cell lung cancer).
[0052] In some embodiments, the antibody targets CD166. Accordingly, in some embodiments, an anti-CD166 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD166 antibody-conjugated nanoparticles are used for the treatment of CD166+ solid tumors (e.g., breast cancer, ovarian cancer, head and neck squamous cell carcinoma, or non-small cell lung cancer).
[0053] In some embodiments, the antibody targets CEACAM5. Accordingly, in some embodiments, an anti-CEACAM5 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CEACAM5 antibody-conjugated nanoparticles are used for the treatment of CEACAM5+ solid tumors (e.g., colorectal cancer, (non-squamous) non-small cell lung cancer, small cell lung cancer, or gastric cancer).
[0054] In some embodiments, the antibody targets GPNMB. Accordingly, in some embodiments, an anti-GPNMB antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-GPNMB antibody-conjugated nanoparticles are used for the treatment of GPNMB+ solid tumors (e.g., breast cancer, triple-negative breast cancer, (squamous) non-small cell lung cancer, (uveal) melanoma, or osteosarcoma).
[0055] In some embodiments, the antibody targets mesothelin. Accordingly, in some embodiments, an anti-mesothelin antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-mesothelin antibody-conjugated nanoparticle is used for the treatment of mesothelin + solid tumors (e.g., mesothelioma, (non-small cell) lung cancer, ovarian cancer, or pancreatic cancer). Accordingly, in one embodiment, an antibody-conjugated nanoparticle containing a cytotoxic payload is provided for use in the treatment of pancreatic tumors, wherein the antibody binds to mesothelin in membrane-bound form.
[0056] In some embodiments, the antibody targets LIV1A. Accordingly, in some embodiments, an anti-LIV1A antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-LIV1A antibody-conjugated nanoparticles are used to treat LIV1A+ solid tumors (e.g., breast cancer such as triple-negative breast cancer).
[0057] In some embodiments, the antibody targets tissue factor (TF). Accordingly, in some embodiments, an anti-TF antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-TF antibody-conjugated nanoparticles are used to treat TF+ solid tumors (e.g., breast cancer such as triple-negative breast cancer).
[0058] In some embodiments, the antibody targets CD71. Accordingly, in some embodiments, an anti-CD71 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD71 antibody-conjugated nanoparticles are used to treat CD71+ solid tumors (e.g., (non-small cell) lung cancer, head and neck squamous cell carcinoma, or ovarian cancer).
[0059] In some embodiments, the antibody targets CD228. Accordingly, in some embodiments, an anti-CD228 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD228 antibody-conjugated nanoparticles are used for the treatment of CD228+ solid tumors (e.g., (cutaneous) melanoma, (pleural) mesothelioma, breast cancer, (non-small cell) lung cancer, colorectal cancer, or pancreatic ductal adenocarcinoma).
[0060] In some embodiments, the antibody targets FRα. Accordingly, in some embodiments, an anti-FRα antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-FRα antibody-conjugated nanoparticles are used for the treatment of FRα+ solid tumors (e.g., ovarian cancer, fallopian tube cancer, or (primary) peritoneal cancer).
[0061] In some embodiments, the antibody targets NaPi2b. Accordingly, in some embodiments, an anti-NaPi2b antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-NaPi2b antibody-conjugated nanoparticles are used for the treatment of NaPi2b+ solid tumors (e.g., ovarian cancer or (non-small cell) lung cancer).
[0062] In some embodiments, the antibody targets Trop-2. Accordingly, in some embodiments, an anti-Trop-2 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-Trop-2 antibody-conjugated nanoparticles are used to treat Trop-2+ solid tumors (e.g., breast cancer such as triple-negative or hormone receptor-positive breast cancer, ovarian cancer, gastric cancer, pancreatic cancer, (non-small cell) lung cancer, or urothelial carcinoma).
[0063] In some embodiments, the antibody targets PSMA. Accordingly, in some embodiments, an anti-PSMA antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-PSMA antibody-conjugated nanoparticles are used for the treatment of PSMA + solid tumors (e.g., prostate cancer or glioblastoma).
[0064] In some embodiments, the antibody targets CD70. Accordingly, in some embodiments, an anti-CD70 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD70 antibody-conjugated nanoparticles are used for the treatment of CD70+ solid tumors (e.g., renal cell carcinoma or non-Hodgkin lymphoma).
[0065] In some embodiments, the antibody targets STEAP1. Accordingly, in some embodiments, an anti-STEAP1 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-STEAP1 antibody-conjugated nanoparticles are used to treat STEAP1+ solid tumors (e.g., prostate cancers such as metastatic castration-resistant prostate cancer).
[0066] In some embodiments, the antibody targets P-cadherin. Accordingly, in some embodiments, an anti-P-cadherin antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-P-cadherin antibody-conjugated nanoparticles are used for the treatment of P-cadherin + solid tumors (e.g., breast cancer such as triple-negative breast cancer, esophageal cancer, or head and neck squamous cell carcinoma).
[0067] In some embodiments, the antibody targets SLITRK6. Accordingly, in some embodiments, an anti-SLITRK6 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-SLITRK6 antibody-conjugated nanoparticles are used for the treatment of SLITRK6+ solid tumors (e.g., urothelial carcinoma).
[0068] In some embodiments, the antibody targets LAMP1. Accordingly, in some embodiments, an anti-LAMP1 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-LAMP1 antibody-conjugated nanoparticles are used for the treatment of LAMP1+ solid tumors.
[0069] In some embodiments, the antibody targets CA9. Accordingly, in some embodiments, an anti-CA9 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CA9 antibody-conjugated nanoparticles are used for the treatment of CA9+ solid tumors.
[0070] In some embodiments, the antibody targets GPR20. Accordingly, in some embodiments, an anti-GPR20 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-GPR20 antibody-conjugated nanoparticles are used for the treatment of GPR20+ solid tumors (e.g., gastrointestinal stromal tumors).
[0071] In some embodiments, the antibody targets CLDN18.2. Accordingly, in some embodiments, an anti-CLDN18.2 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, anti-GPR20 antibody-conjugated nanoparticles are used for the treatment of CLDN18.2+ solid tumors (e.g., tumors of the stomach or pancreas).
[0072] Leucine-rich repeat 15 (LRRC15), FAPα, ANTXR1, TM4SF1, CD25, CD205, B7-H3, and HLA-DR are target antigens in several tumor microenvironments.
[0073] In some embodiments, the antibody targets LRRC15. Accordingly, in some embodiments, an anti-LRRC15 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-LRRC15 antibody-conjugated nanoparticles are used to treat solid tumors (e.g., sarcomas such as undifferentiated pleomorphic sarcoma, head and neck squamous cell carcinoma, or breast cancer).
[0074] In some embodiments, the antibody targets FAPα. Accordingly, in some embodiments, an anti-FAPα antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-FAPα antibody-conjugated nanoparticles are used for the treatment of solid tumors (e.g., (non-small cell) lung cancer).
[0075] In some embodiments, the antibody targets ANTXR1. Accordingly, in some embodiments, an anti-ANTXR1 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-ANTXR1 antibody-conjugated nanoparticles are used for the treatment of solid tumors.
[0076] In some embodiments, the antibody targets TM4SF1. Accordingly, in some embodiments, an anti-TM4SF1 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-TM4SF1 antibody-conjugated nanoparticles are used for the treatment of solid tumors.
[0077] In some embodiments, the antibody targets CD25. Accordingly, in some embodiments, an anti-CD25 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD25 antibody-conjugated nanoparticles are used for the treatment of solid tumors (e.g., solid tumors with CD25+ Treg cells) or CD25+ hematological malignancies.
[0078] In some embodiments, the antibody targets CD205. Therefore, in some embodiments, an anti-CD205 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD205 antibody-conjugated nanoparticles are used to treat solid tumors (e.g., non-Hodgkin lymphoma).
[0079] In some embodiments, the antibody targets B7-H3. Accordingly, in some embodiments, an anti-B7-H3 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-B7-H3 antibody-conjugated nanoparticles are used for the treatment of solid tumors.
[0080] In some embodiments, the antibody targets HLA-DR. Accordingly, in some embodiments, an anti-HLA-DR antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-HLA-DR antibody-conjugated nanoparticles are used for the treatment of cancer (e.g., hematological malignancies or melanoma).
[0081] Delta-like protein 1 homolog (DLK-1), delta-like ligand 3 (DLL3), ephrin A4 (EFNA4), PTK7, ROR1, 5T4, and KAAG1 are target antigens expressed by several stem cells.
[0082] In some embodiments, the antibody targets DLK-1. Accordingly, in some embodiments, an anti-DLK-1 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-DLK1 antibody-conjugated nanoparticles are used for the treatment of solid tumors (e.g., liver cancer).
[0083] In some embodiments, the antibody targets DLL-3. Accordingly, in some embodiments, an anti-DLL-3 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-DLL-3 antibody-conjugated nanoparticles are used for the treatment of solid tumors (e.g., (small cell) lung cancer).
[0084] In some embodiments, the antibody targets EFNA4. Accordingly, in some embodiments, an anti-EFNA4 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-EFNA4 antibody-conjugated nanoparticles are used for the treatment of solid tumors.
[0085] In some embodiments, the antibody targets PTK7. Accordingly, in some embodiments, an anti-PTK7 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-PTK7 antibody-conjugated nanoparticles are used to treat solid tumors (e.g., breast, ovarian, or (non-small cell) lung cancer, such as triple-negative breast cancer).
[0086] In some embodiments, the antibody targets ROR1. Accordingly, in some embodiments, an anti-ROR1 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-ROR1 antibody-conjugated nanoparticles are used to treat solid tumors (e.g., breast cancer such as triple-negative breast cancer).
[0087] In some embodiments, the antibody targets 5T4. Accordingly, in some embodiments, an anti-5T4 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-5T4 antibody-conjugated nanoparticles are used for the treatment of solid tumors.
[0088] In some embodiments, the antibody targets KAAG1. Accordingly, in some embodiments, an anti-KAAG1 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-KAAG1 antibody-conjugated nanoparticles are used for the treatment of solid tumors.
[0089] In relation to cancer treatment, the therapeutic payload may be a gene editing payload capable of knocking out or disrupting genes essential for the survival or replication of cancer cells. For example, in the treatment of CML, the gene editing payload may be capable of knocking out or disrupting BCR, ABL1, SOS1, GRB2, or GAB2. For example, in the treatment of lymphoma, the gene editing payload may be capable of knocking out or disrupting EBF1, POU2AF1, PAX5, MEF2B, or CCND3. In another embodiment, the therapeutic payload is a cytotoxic payload. For example, in one embodiment, an anti-mesothelin antibody conjugated to nanoparticles containing a cytotoxic payload is used for the treatment of mesothelin + cancer, e.g., mesothelin + pancreatic tumor.
[0090] In some embodiments, the antibody targets hematopoietic stem cell (HSC) surface antigens. Accordingly, in some embodiments, anti-HSC cell surface antigen antibodies are provided that are conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-HSC cell surface antigen antibody conjugated nanoparticles are used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-HSC cell surface antigen antibody conjugated nanoparticles are used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-HSC cell surface antigen antibody conjugated nanoparticles are used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0091] CD34, Gpr56, Gpr97, CD49, CD49f, CD90, CD117, and endomucin are typically expressed in hematopoietic stem cells.
[0092] In some embodiments, the antibody targets CD34. Accordingly, in some embodiments, an anti-CD34 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD34 antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-CD34 antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-CD34 antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0093] In some embodiments, the antibody targets Gpr56. Accordingly, in some embodiments, an anti-Gpr56 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-Gpr56 antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-Gpr56 antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-Gpr56 antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia). In some embodiments, anti-Gpr56 antibody-conjugated nanoparticles are used to treat Gpr56+ solid tumors (e.g., brain cancers such as gliomas).
[0094] In some embodiments, the antibody targets Gpr97. Accordingly, in some embodiments, an anti-Gpr97 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-Gpr97 antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-Gpr97 antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-Gpr97 antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0095] In some embodiments, the antibody targets CD49. Accordingly, in some embodiments, an anti-CD49 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD49 antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-CD49 antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-CD49 antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0096] In some embodiments, the antibody targets CD49f. Accordingly, in some embodiments, an anti-CD49f antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD49f antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-CD49f antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-CD49f antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0097] In some embodiments, the antibody targets CD90. Accordingly, in some embodiments, an anti-CD90 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD90 antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-CD90 antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-CD90 antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0098] In some embodiments, the antibody targets CD117. Accordingly, in some embodiments, an anti-CD117 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD117 antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-CD117 antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-CD117 antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0099] In some embodiments, the antibody targets endomucin. Accordingly, in some embodiments, an anti-endomucin antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-endomucin antibody-conjugated nanoparticle is used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the anti-endomucin antibody-conjugated nanoparticle is used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the anti-endomucin antibody-conjugated nanoparticle is used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0100] In some embodiments, the antibody is a bispecific antibody targeting two of the following antigens: CD34, Gpr56, Gpr97, CD49, CD49f, CD90, CD117, and endomucin. In some embodiments, the bispecific antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the bispecific antibody-conjugated nanoparticles are used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the bispecific antibody-conjugated nanoparticles are used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, the bispecific antibody-conjugated nanoparticles are used to treat cancer (e.g., hematological or lymphoid cancers, e.g., multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0101] In some embodiments, the antibody is a multispecific antibody targeting three or more (e.g., four, five, or six) of the following antigens: CD34, Gpr56, Gpr97, CD49, CD49f, CD90, CD117, and endomucin. In some embodiments, the multispecific antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the multispecific antibody-conjugated nanoparticles are used to treat hereditary blood disorders (e.g., sickle cell disease, hemoglobinopathy, or thalassemia). In some embodiments, the multispecific antibody-conjugated nanoparticles are used to treat congenital immunodeficiency disorders (e.g., severe combined immunodeficiency or hypogammaglobulinemia). In some embodiments, multispecific antibody-conjugated nanoparticles are used to treat cancer (e.g., hematological or lymphoid cancers, such as multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, chronic myeloid leukemia, or chronic lymphocytic leukemia).
[0102] In connection with the treatment of hereditary blood disorders or congenital immunodeficiency, the therapeutic payload may be a gene-editing payload capable of correcting the genetic defect causing the hereditary blood disorder or congenital immunodeficiency.
[0103] In relation to cancer treatment, the therapeutic payload may be a gene editing payload capable of knocking out or disrupting genes essential for the survival or replication of (cancer) cells (e.g., genes encoding polymerase or polymerase subunits). In another embodiment, the therapeutic payload is a cytotoxic payload. For example, in one embodiment, an anti-Gpr56 antibody conjugated to nanoparticles containing a cytotoxic payload is used to treat Gpr56+ solid tumors, such as Gpr56+ brain cancer (e.g., Gpr56+ glioma), and optionally, the antibody-conjugated nanoparticles are delivered directly to the tumor through the skull.
[0104] In a preferred embodiment, the antibody is an anti-CD34 antibody. In another preferred embodiment, the antibody is an anti-Gpr56 antibody.
[0105] In this embodiment, the antibody is bispecific. For example, the antibody may be a bispecific anti-CD34 and anti-Gpr56 antibody. Alternatively, the antibody may be a multispecific antibody.
[0106] CD34 is a cell surface antigen of pluripotent progenitor cells (MPP), pluripotent lymphocyte progenitor cells (MLP), common myeloid progenitor cells (CMP), megakaryocyte erythrocyte progenitor cells (MEP), megakaryocyte colony-forming units (CFU-Mk), erythrocyte burst-forming units (BFU-E), granulocyte-macrophage progenitor cells (GMP), and common lymphoid progenitor cells (CLP).
[0107] CD45RA is a cell surface antigen of MLP, GMP, and CLP cells.
[0108] CD38 is a cell surface antigen of CMP, BFU-E, and GMP cells. It is also present at low levels in MEP cells and some CLP cells.
[0109] In some embodiments, the antibody targets CD34. Therefore, in some embodiments, an anti-CD34 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD34 antibody-conjugated nanoparticles are used to treat blood cancers (e.g., leukemia).
[0110] In some embodiments, the antibody targets CD45RA. Accordingly, in some embodiments, an anti-CD45RA antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD45RA antibody-conjugated nanoparticles are used to treat blood cancers (e.g., leukemia).
[0111] In some embodiments, the antibody targets CD38. Accordingly, in some embodiments, an anti-CD38 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD38 antibody-conjugated nanoparticles are used to treat blood cancers (e.g., leukemia).
[0112] In some embodiments, the antibody is a bispecific antibody targeting CD34 and CD45RA, CD34 and CD38, or CD45RA and CD38. In some embodiments, the bispecific antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the antibody-conjugated nanoparticles are used to treat blood cancers (e.g., leukemia).
[0113] In some embodiments, the antibody is a trispecific antibody targeting CD34, CD38, and CD45RA. In some embodiments, the trispecific antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the antibody-conjugated nanoparticles are used to treat blood cancers (e.g., leukemia).
[0114] In connection with the treatment of blood cancers (e.g., leukemia), the therapeutic payload may be a gene editing payload capable of knocking out or disrupting genes essential for the survival or replication of (cancer) cells (e.g., genes encoding polymerase or polymerase subunits).
[0115] In some embodiments, the antibody targets a T cell surface antigen. Accordingly, in some embodiments, an anti-T cell surface antigen antibody is provided, conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-T cell surface antigen antibody-conjugated nanoparticle is used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific T cell responses. In some embodiments, the anti-T cell surface antigen antibody-conjugated nanoparticle is used to treat cancer by enhancing the activity of neoantigen-specific T cells. In some embodiments, the gene editing payload is capable of knocking out or disrupting PD-1.
[0116] CD4, CD8, CD3, CTLA4, TCR, TCRα, and TCRβ are T cell surface antigens.
[0117] In some embodiments, the antibody targets CD4. Accordingly, in some embodiments, an anti-CD4 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD4 antibody-conjugated nanoparticle is used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific T cell responses. In some embodiments, the anti-CD4 surface antigen antibody-conjugated nanoparticle is used to treat cancer by enhancing the activity of neoantigen-specific T cells. In some embodiments, the gene editing payload is capable of knocking out or disrupting PD-1.
[0118] In some embodiments, the antibody targets CD8. Accordingly, in some embodiments, an anti-CD8 antibody is provided, conjugated onto nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD8 antibody-conjugated nanoparticles are used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific T cell responses. In some embodiments, the anti-CD4 surface antigen antibody-conjugated nanoparticles are used to treat cancer by enhancing the activity of neoantigen-specific T cells. In some embodiments, the gene editing payload is capable of knocking out or disrupting PD-1.
[0119] In some embodiments, the antibody targets CD3. Accordingly, in some embodiments, an anti-CD3 antibody is provided that is conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD3 antibody-conjugated nanoparticle is used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific T cell responses. In some embodiments, the anti-CD3 surface antigen antibody-conjugated nanoparticle is used to treat cancer by enhancing the activity of neoantigen-specific T cells. In some embodiments, the gene editing payload is capable of knocking out or disrupting PD-1.
[0120] In some embodiments, the antibody targets CTLA4. Accordingly, in some embodiments, an anti-CTLA4 antibody is provided conjugated to nanoparticles containing a cytotoxic payload. In some embodiments, an anti-CTLA4 antibody is provided conjugated to nanoparticles containing a gene editing payload, and optionally, the gene editing payload can disrupt or knock out genes essential for T cell survival or replication (e.g., genes encoding polymerase or polymerase subunits). In some embodiments, anti-CTLA4 antibody-conjugated nanoparticles are used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific cytotoxic T cell responses by reducing the number of regulatory T cells in tumors. In some embodiments, anti-CTLA4 surface antigen antibody-conjugated nanoparticles are used to treat cancer by enhancing the activity of neoantigen-specific (cytotoxic) T cells. In some embodiments, the gene editing payload can knock out or disrupt PD-1.
[0121] In some embodiments, the antibody targets the TCR. Accordingly, in some embodiments, an anti-TCR antibody is provided, conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-TCR antibody-conjugated nanoparticle is used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific T cell responses. In some embodiments, the anti-TCR surface antigen antibody-conjugated nanoparticle is used to treat cancer by enhancing the activity of neoantigen-specific T cells. In some embodiments, the gene editing payload is capable of knocking out or disrupting PD-1.
[0122] In some embodiments, the antibody targets TCRα. Accordingly, in some embodiments, anti-TCRα antibodies are provided that are conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, anti-TCRα antibody-conjugated nanoparticles are used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific T cell responses. In some embodiments, anti-TCRα surface antigen antibody-conjugated nanoparticles are used to treat cancer by enhancing neoantigen-specific T cell activity. In some embodiments, the gene editing payload is capable of knocking out or disrupting PD-1.
[0123] In some embodiments, the antibody targets TCRβ. Accordingly, in some embodiments, anti-TCRβ antibodies are provided that are conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, anti-TCRβ antibody-conjugated nanoparticles are used to treat cancer or pathogenic diseases by increasing cancer or pathogen-specific T cell responses. In some embodiments, anti-TCRβ surface antigen antibody-conjugated nanoparticles are used to treat cancer by enhancing the activity of neoantigen-specific T cells. In some embodiments, the gene editing payload is capable of knocking out or disrupting PD-1.
[0124] In some embodiments, the antibody targets a dendritic cell surface antigen. Accordingly, in some embodiments, an anti-dendritic cell surface antigen antibody is provided, conjugated to a nanoparticle containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-dendritic cell surface antigen antibody-conjugated nanoparticle is used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0125] HLA-DR and CD40 are surface antigens of dendritic cells. CD1c, Dectin 1, Dectin 2, CD141, CLEC9A, and XCR1 are conventional surface antigens of dendritic cells. CD303, CD304, and CD123 are surface antigens of plasmacytoid dendritic cells. CD14, CD209, and factor XIIIA are surface antigens of CD14+ monocyte-associated dendritic cells. CD16, CX3CR1, and SLAN are surface antigens of CD16+ monocyte-associated dendritic cells. CD1c is a surface antigen of inflammatory dendritic cells. In some embodiments, the antibody targets HLA-DR. Accordingly, in some embodiments, an anti-HLA-DR antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-HLA-DR antibody-conjugated nanoparticles are used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0126] In some embodiments, the antibody targets CD40. Accordingly, in some embodiments, an anti-CD40 antibody is provided that is conjugated to nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the anti-CD40 antibody-conjugated nanoparticles are used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0127] In some embodiments, the antibody targets one of the following antigens: CD1c, Dectin 1, Dectin 2, CD141, CLEC9A, and XCR1. In some embodiments, the antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the antibody-conjugated nanoparticles are used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0128] In some embodiments, the antibody targets one of the following antigens: CD303, CD304, and CD123. In some embodiments, the antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the antibody-conjugated nanoparticles are used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0129] In some embodiments, the antibody targets one of the following antigens: CD14, CD209, and factor XIIIA. In some embodiments, the antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the antibody-conjugated nanoparticles are used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0130] In some embodiments, the antibody targets one of the following antigens: CD16, CX3CR1, and SLAN. In some embodiments, the antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the antibody-conjugated nanoparticles are used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0131] In some embodiments, the antibody targets CD1c. In some embodiments, the antibody is conjugated into nanoparticles containing a therapeutic payload (e.g., a gene editing payload). In some embodiments, the antibody-conjugated nanoparticles are used to prevent transplant rejection. In some embodiments, the gene editing payload is capable of knocking out or disrupting CD40.
[0132] In some embodiments, the antibody is a bispecific or multispecific HCAb, for example, a bispecific or multispecific human or humanized HCAb. In some embodiments, the antibody is a bispecific or multispecific antibody derived from one or more HCAb antibodies and one or more H2L2 antibodies, for example, a bispecific antibody may contain one light chain and two heavy chains.
[0133] The present invention further provides an anti-CD34 antibody comprising a heavy chain variable region (VH) containing three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) containing three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 containing the amino acid sequence of SEQ ID NO: 1; HCDR2 containing the amino acid sequence of SEQ ID NO: 2; and HCDR3 containing the amino acid sequence of SEQ ID NO: 3; and VL comprises LCDR1 containing the amino acid sequence of SEQ ID NO: 4; LCDR2 containing the amino acid sequence of SEQ ID NO: 5; and LCDR3 containing the amino acid sequence of SEQ ID NO: 6.
[0134] The anti-CD34 antibody of the present invention may include a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 7. The anti-CD34 antibody of the present invention may include a light chain variable region containing the amino acid sequence of SEQ ID NO: 8. The anti-CD34 antibody of the present invention may include a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 7 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 8.
[0135] The present invention further provides an anti-CD34 antibody that binds to the same epitope as the antibody containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and the light chain variable region of the amino acid sequence of SEQ ID NO: 8.
[0136] The present invention further provides an anti-CD34 antibody that binds to the same epitope as the heavy chain-only antibody, which includes the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7.
[0137] The present invention further provides an anti-CD34 antibody that competes with antibodies containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and the light chain variable region of the amino acid sequence of SEQ ID NO: 8 for binding to CD34.
[0138] The present invention further provides an anti-CD34 antibody that, in terms of binding to CD34, competes only with antibodies that contain the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7.
[0139] In some embodiments, the antibody includes a heavy chain variable region of the amino acid sequence of SEQ ID NO: 7.
[0140] In some embodiments, the antibody includes an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7.
[0141] In some embodiments, the antibody includes a light chain variable region of the amino acid sequence of SEQ ID NO: 8.
[0142] In some embodiments, the antibody includes an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the light chain variable region of the amino acid sequence of SEQ ID NO: 8.
[0143] In some embodiments, the antibody comprises (i) an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7, and (ii) an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the light chain variable region of the amino acid sequence of SEQ ID NO: 8.
[0144] The present invention further, i. For the heavy chain CDR1, the sequence is at least 90% identical to sequence number 1. ii. For the heavy chain CDR2, a sequence that is at least 90% identical to sequence number 2, iii. For the heavy chain CDR3, a sequence that is at least 90% identical to sequence number 3, iv. Regarding the CDR1 of the light chain, a sequence that is at least 90% identical to sequence number 4, v. A sequence of CDR2 in the light chain that is at least 90% identical to sequence number 5, and vi. For CDR3 of the light chain, a sequence that is at least 90% identical to sequence number 6, We provide an anti-CD34 antibody containing a complementarity-determining region (CDR) having the following characteristics: The antibody competes for binding to CD34 with antibodies containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and the light chain variable region of the amino acid sequence of SEQ ID NO: 8.
[0145] The present invention further, i. For the heavy chain CDR1, a sequence that is at least 95% identical to sequence number 1, ii. For the heavy chain CDR2, a sequence that is at least 95% identical to sequence number 2, iii. For the heavy chain CDR3, a sequence that is at least 95% identical to sequence number 3, iv. For CDR1 of the light chain, a sequence that is at least 95% identical to sequence number 4, v. A sequence of CDR2 in the light chain that is at least 95% identical to sequence number 5, and vi. For CDR3 of the light chain, a sequence that is at least 95% identical to sequence number 6, We provide an anti-CD34 antibody containing a complementarity-determining region (CDR) having the following characteristics: The antibody competes for binding to CD34 with antibodies containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 7 and the light chain variable region of the amino acid sequence of SEQ ID NO: 8.
[0146] The present invention also provides an anti-Gpr56 antibody comprising a heavy chain variable region (VH) containing three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) containing three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 containing the amino acid sequence of SEQ ID NO: 9; HCDR2 containing the amino acid sequence of SEQ ID NO: 10; and HCDR3 containing the amino acid sequence of SEQ ID NO: 11; and VL comprises LCDR1 containing the amino acid sequence of SEQ ID NO: 12; LCDR2 containing the amino acid sequence of SEQ ID NO: 13; and LCDR3 containing the amino acid sequence of SEQ ID NO: 14.
[0147] The anti-Gpr56 antibody of the present invention may include a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 15. The anti-Gpr56 antibody of the present invention may include a light chain variable region containing the amino acid sequence of SEQ ID NO: 16. The anti-Gpr56 antibody of the present invention may include a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 15 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 16.
[0148] The present invention further provides an anti-Gpr56 antibody that binds to the same epitope as the antibody containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15 and the light chain variable region of the amino acid sequence of SEQ ID NO: 16.
[0149] The present invention further provides an anti-Gpr56 antibody that binds to the same epitope as the heavy chain-only antibody, which includes the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15.
[0150] The present invention further provides an anti-Gpr56 antibody that competes with antibodies containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15 and the light chain variable region of the amino acid sequence of SEQ ID NO: 16 for binding to Gpr56.
[0151] The present invention further provides an anti-Gpr56 antibody that, in terms of binding to Gpr56, competes only with heavy chain antibodies that include the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15.
[0152] In some embodiments, the antibody includes a heavy chain variable region of the amino acid sequence of SEQ ID NO: 15.
[0153] In some embodiments, the antibody includes an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15.
[0154] In some embodiments, the antibody includes a light chain variable region of the amino acid sequence of SEQ ID NO: 16.
[0155] In some embodiments, the antibody includes an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the light chain variable region of the amino acid sequence of SEQ ID NO: 16.
[0156] In some embodiments, the antibody comprises (i) an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15, and (ii) an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the light chain variable region of the amino acid sequence of SEQ ID NO: 16.
[0157] The present invention further, i. For the heavy chain CDR1, a sequence that is at least 90% identical to sequence number 9, ii. For the heavy chain CDR2, a sequence that is at least 90% identical to sequence number 10, iii. For the heavy chain CDR3, a sequence that is at least 90% identical to sequence number 11, iv. Regarding the CDR1 of the light chain, a sequence that is at least 90% identical to sequence number 12, v. Regarding the CDR2 of the light chain, a sequence that is at least 90% identical to sequence number 13, and vi. For CDR3 of the light chain, a sequence that is at least 90% identical to sequence number 14. We provide an anti-Gpr56 antibody containing a complementarity-determining region (CDR) having the following characteristics: The antibody competes for binding to Gpr56 with antibodies containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15 and the light chain variable region of the amino acid sequence of SEQ ID NO: 16.
[0158] The present invention further, i. For the heavy chain CDR1, a sequence that is at least 95% identical to sequence number 9, ii. For the heavy chain CDR2, a sequence that is at least 95% identical to sequence number 10, iii. For the heavy chain CDR3, a sequence that is at least 95% identical to sequence number 11, iv. Regarding the CDR1 of the light chain, a sequence that is at least 95% identical to sequence number 12, v. A sequence of CDR2 in the light chain that is at least 95% identical to sequence number 13, and vi. For CDR3 of the light chain, a sequence that is at least 95% identical to sequence number 14. We provide an anti-Gpr56 antibody containing a complementarity-determining region (CDR) having the following characteristics: The antibody competes for binding to Gpr56 with antibodies containing the heavy chain variable region of the amino acid sequence of SEQ ID NO: 15 and the light chain variable region of the amino acid sequence of SEQ ID NO: 16.
[0159] The following sections identify features that can be combined with each of the previous embodiments as needed.
[0160] In some embodiments, the antibody reacts with the target antigen (e.g., CD34 or Gpr56) for 10 -7 M or less, 10 -8 M or less, 10 -9 M or less, or 10 -10 K below MD Binding occurs via surface plasmon resonance. In some embodiments, antibody binding affinity is determined using the Octet® RED96 system (ForteBio, Inc.). For example, a Flag-tagged S1 domain or Flag-tagged S2 domain can be immobilized on an anti-flag biosensor and incubated with antibodies of various concentrations in solution, and then binding data is collected. In some embodiments, antibody binding affinity is determined by surface plasmon resonance.
[0161] In some embodiments, whether a test antibody competes with a reference antibody for binding to a target antigen (e.g., CD34 or Gpr56) is determined using an in vitro binding competition assay. For example, a flag-tagged antigen (e.g., CD34 or Gpr56) may be immobilized on an anti-flag biosensor, the association of the reference antibody with the immobilized flag-tagged antigen is then measured (e.g., using the Octet® RED96 system, ForteBio, Inc.), and the degree of addition-binding is then assessed by exposing the test antibody to the immobilized flag-tagged antigen in the presence of the reference antibody.
[0162] The anti-CD34 or anti-Gpr56 antibody of the present invention further comprises a constant region. Preferably, the anti-CD34 or anti-Gpr56 antibody of the present invention comprises a human constant region, such as a human IgG1 constant region.
[0163] In a preferred embodiment, the antibody conjugate of the present invention comprises the anti-CD34 or anti-Gpr56 antibody of the present invention.
[0164] <Napolecules> In one embodiment, the nanoparticles of the antibody-conjugated nanoparticles have a diameter of 1 to 500 nm. Preferably, the nanoparticles have a diameter of 150 to 400 nm, for example, 200 to 400 nm. The diameter of the nanoparticles is obtained by any preferred method such as dynamic light scattering, nanoparticle tracking analysis, transmission electron microscopy, scanning electron microscopy, atomic force microscopy, optical correlation spectroscopy, X-ray diffraction, or time-of-flight mass spectrometry. Preferably, the diameter of the nanoparticles is measured by dynamic light scattering or nanoparticle tracking analysis. The diameter of the nanoparticles is preferably measured when the nanoparticles contain a payload, most preferably when the nanoparticles encapsulate the payload so that the payload is inside the nanoparticle.
[0165] Preferably, the nanoparticles are biodegradable. Furthermore, the nanoparticles are preferably non-toxic, and more preferably non-toxic to human patients.
[0166] In one embodiment, the nanoparticles have a negative zeta potential. In one embodiment, the zeta potential is -30 to 0 mV, for example, -25 to -5 mV.
[0167] In one embodiment, the nanoparticles comprise one or more of chitosan, alginate, xanthan gum, cellulose, poly(lactic acid-coglycolic acid), polyethylene glycol, poly(propylene glycol), poly(aspartic acid), and poly(lactic acid). In one embodiment, the nanoparticles comprise one of liposomes, polymeric micelles, and dendrimers [1]. In one embodiment, the nanoparticles comprise a biodegradable polymer.
[0168] Nanoparticles can be surface-modified; for example, they can be coated with polyethylene glycol (PEG).
[0169] Nanoparticles can be synthesized using any suitable method, such as solvent extraction, microfluidic nanoparticle manufacturing, dialysis, solution casting, polycarbonate membrane extrusion, high-pressure homogenization, reverse-phase evaporation, sonication, or lipid membrane hydration sonication extrusion (see, for example, [2]).
[0170] In one embodiment, the nanoparticles comprise poly(lactic acid-coglycolic acid) (PLGA). In another embodiment, the nanoparticles comprise polyethylene glycol (PEG). In a preferred embodiment, the nanoparticles comprise PLGA and PEG. More preferably, the nanoparticles comprise essentially PLGA and PEG, and optionally, the nanoparticles comprise PLGA and PEG. In one embodiment, the nanoparticles comprise a PLGA core surface-coated with PEG.
[0171] Nanoparticles containing or comprising PLGA and / or PEG can be synthesized by any preferred method, such as emulsification evaporation, salting out, nanoprecipitation, or the use of microfluidics (see, for example, Danhier 2012 Journal of Controlled Release 161(2):505-522).
[0172] The nanoparticles are preferably taken up by cells and released into the cells, thereby enabling direct delivery of the payload into the intracellular space. In one embodiment, antibody-conjugated nanoparticles are taken up by cells via ingestion. In particular, when the diameter of the nanoparticles is less than 500 nm, the nanoparticles are taken up by cells via ingestion [3].
[0173] In one embodiment, antibody-conjugated nanoparticles are taken up by cells via phagocytosis. In one embodiment, the nanoparticles are configured to release a payload in a pH-dependent manner, for example, the payload is released when the pH is 7, 6.5, 6, 5.5, or less than 5 (see, for example, [4]).
[0174] <payload> The antibody-conjugate nanoparticles of the present invention include a payload.
[0175] Preferably, the payload is encapsulated within nanoparticles such that the payload is located inside the nanoparticles. In one embodiment, the payload is encapsulated inside the PLGA core of the nanoparticles. Encapsulation within the nanoparticles protects the payload from premature degradation. Additionally or alternatively, the payload may be conjugated into the nanoparticles.
[0176] In one embodiment, the payload is a therapeutic payload, which may be any payload that treats or improves the symptoms of one or more diseases, and can be administered to a patient in need. In one embodiment, the payload is a drug, for example, a drug for treating cancer, for example, a chemotherapy drug. In one embodiment, the payload is a toxin, such as an alkylating agent. A toxin as used herein is any molecule that kills cells to which the payload is delivered.
[0177] In one embodiment, the payload, optionally, the therapeutic payload, includes at least one of the following: a drug, a protein, RNA, DNA, or a contrast agent.
[0178] In a preferred embodiment, the payload is a gene editing payload. The gene editing payload is any payload configured to edit, i.e., modify, the patient's genome or the genome of a cell in any way. The gene editing preferably treats or improves the symptoms of a disorder, such as a genetic disorder, that the patient is suffering from. In a preferred embodiment, the gene editing payload alters the DNA sequence of the patient's genome or the genome of a cell. Alternatively, the gene editing payload alters the patient's genome or the genome of a cell by causing epigenetic changes, regulating gene transcription, or stopping DNA replication.
[0179] The gene editing payload preferably comprises a nuclease, most preferably an endonuclease, which is configured to induce a single-strand or double-strand break at a specific or nonspecific site in the patient's genome or cell genome. The specific site may be a specific gene or a specific sequence within the patient's genome or cell genome. The non-specific site may be any site in the genome; for example, the nuclease may induce a double-strand break at a random site in the genome.
[0180] In one embodiment, the payload comprises at least one of the following: meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered, regularly spaced short palindromic repeat (CRISPR) nuclease (see, for example, [5]). Alternatively, the payload comprises mRNA or DNA encoding at least one of the following: meganuclease, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), and clustered, regularly spaced short palindromic repeat (CRISPR) nuclease.
[0181] In a preferred embodiment, the payload comprises a CRISPR nuclease, optionally selected from: CRISPR-related protein 9 (Cas9), CRISPR-related protein 12a (Cas12a, also known as Cpf1), CRISPR-related protein 13 (Cas13), CRISPR-related protein 12b (Cas12b), CRISPR-related protein X (CasX, also known as Cas12e), CRISPR-related protein Y (CasY), and CRISPR-related protein 14a (Cas14a). A suitable CRISPR nuclease may be selected based, for example, on selectivity and / or size requirements, such that the nuclease must be small enough to be encapsulated in nanoparticles (e.g., https: / / bitesizebio.com / 46146 / crispr-nucleases-the-ultimate-guide / and https: / / www.synthego.com / guide / how-to-use-crispr / cas9-nuclease-variants). If Cas9 is a nuclease, it may be derived from Streptococcus pyogenes (SpCas9), Staphylococcus aureus (SaCas9), Streptococcus thermophilus (StCas9), Neisseria meningitidis (NmCas9), Francisella novicida (FnCas9), Streptococcus canis (ScCas9), or Campylobacter jejuni (CjCas9). The CRISPR nuclease may be derived from a naturally occurring CRISPR nuclease or a modified CRISPR nuclease. In particular, the gene editing payload may include a modified CRISPR nuclease selected from the following: high fidelity SpCas9 (SpCas9-HF1, eSpCas9-1.1), SpCas9 with relaxed PAM (SpCas9-NG), SpCas9 nickase (Cas9n), or nuclease-inactive SpCas9 (dCas9).Nuclease-inactive SpCas9 is preferably used when the gene editing payload is configured to alter the patient's genome or cellular genome by epigenetic changes or regulation of gene transcription [6]. Nuclease-inactive SpCas9 may also be used to halt DNA replication within cells [7], for example, to halt DNA replication within tumor cells, thereby interrupting the process of cell division and delaying tumor growth. When SpCas9 nickase is used, preferably the gene editing payload includes two versions of nickase to produce double-strand breaks, with each nickase producing a single-strand break at the target site.
[0182] Preferably, the nuclease is SpCas9.
[0183] Preferably, the nuclease is fused to one or more nuclear localization signal sequences.
[0184] Most preferably, the nuclease is Cas9 fused to one or more nuclear localization signal (NLS) sequences (e.g., Cas9 fused to three NLS sequences).
[0185] In embodiments in which the payload contains a CRISPR nuclease, the payload further contains a CRISPR RNA (crRNA) and a transactivating crRNA (tracrRNA). Both crRNA and tracrRNA function as guides for the CRISPR nuclease (cr:tracrRNA guide).
[0186] In alternative embodiments where the payload includes a CRISPR nuclease, the payload further includes a single guide RNA (gRNA). The gRNA contains a short crRNA sequence that is used by the CRISPR nuclease to recognize target DNA and is optionally fused to a scaffolding tracrRNA sequence. Together, the CRISPR nuclease and gRNA form a CRISPR ribonucleoprotein complex. In one embodiment, the gRNA is 17 bp to 24 bp in length, for example, 17 bp, 18 bp, 19 bp, 20 bp, 21 bp, 22 bp, 23 bp, or 24 bp. In another embodiment, the gRNA is 19 to 21 bp in length, for example, 20 bp.
[0187] cr:tracrRNA or gRNA is complementary to the target site so that, when present with a CRISPR nuclease in the CRISPR ribonucleoprotein complex, the CRISPR nuclease creates a double-strand break at the target site. The target site must precede a protospacer adjacent motif (PAM), which is a short DNA sequence typically 2–6 base pairs in length (located upstream of the DNA region targeted for cleavage by the CRISPR ribonucleoprotein complex). The PAM is required for the CRISPR nuclease to cleave the DNA; therefore, CRISPR nucleases may be selected alternatively or additionally based on the nuclease's PAM requirement, i.e., a nuclease may be selected if it has a PAM sequence found at the target site.
[0188] In some embodiments, the gene editing payload further includes a donor DNA molecule containing a template that can be recombined with the patient's genome or the cell's genome at double-strand break sites. For example, the donor DNA molecule may be double-stranded and can be incorporated into the patient's genome or the cell's genome by homologous recombination. Alternatively, the donor DNA molecule may be single-stranded and act as a template for homology-directed repair at double-strand break sites. In these embodiments, the gene editing payload can "knock in" a gene, for example, replacing a pathogenic defect gene with a wild-type gene, thereby restoring the normal function of that gene.
[0189] In alternative embodiments, the gene editing payload does not contain a donor DNA molecule, and the double-strand break is repaired by a cellular repair mechanism that causes sequence modification at the site that produces a frameshift or deletion mutation at the target locus, such as any mechanism by which an indel is created, such as non-homologous end joining or microhomology-mediated end joining. Such a frameshift or deletion mutation causes loss of function at the double-strand break site. In these embodiments, the gene editing payload is capable of "knocking out" a gene, for example, an oncogene can be knocked out.
[0190] In one embodiment, the gene editing payload is configured to edit one or more genes or loci associated with a disease or disorder, such as a hereditary disease or disorder, cancer, or a non-cancerous tumor. If the disease or disorder is a hereditary disease or disorder, the gene editing payload may be configured to edit a pathogenic gene or locus. In this embodiment, the gene editing payload may be configured to modify the pathogenic gene or locus by homologous recombination with a donor DNA strand containing a wild-type gene or locus sequence or subsequence. It will be understood that the wild-type gene or locus is any non-pathogenic sequence of the gene or locus, in particular any sequence of the gene or locus that does not result in a disease phenotype.
[0191] If the disease or disorder is cancer or a non-cancerous tumor, the gene editing payload may be configured to induce a double-strand break in one or more genes or loci essential for cell survival, e.g., any gene or locus [8]. For example, a gene encoding polymerase or a polymerase subunit.
[0192] In one embodiment, the gene editing payload is configured to edit any one or more of the following genes or loci in the patient's genome or cell genome: γ-globin, cystic fibrosis membrane conductance regulator (CFTR), dystrophin, keratin 5, keratin 14, desmoplakin, placophyllin-1, placoglobin, plectin, dystonin, exophilin 5, TGM5, laminin subunit α-3, laminin subunit β-3, laminin subunit γ-2, collagen XVII, integrin α-6, CD49d, integrin α-3, collagen α-1(VII), fermitin family homolog 1, ferrokeratase, Fanconi anemia supplementation groups A, B, C, D1, D2 E, F, G, I, J, L, M, N, P, or S, RAD51 homolog C, DNA repair endonuclease XPF, FMR1, frataxin, galactose-1-phosphate uridyltransferase, galactokinase, UDP-glucose-4-epimerase, PRNP, ATP-binding cassette subfamily A member 12, factor VIII, uroporphyrinogen III decarboxylase, huntingtin, fibroblast growth factor receptor 3, tumor protein p53, myostatin, RAG1, RAG2, type I collagen α1, type I collagen α2, polycystin 1, polycystin 2, protein C, protein S, hemoglobin β, hemoglobin α, hexosaminidase A, fibroblast growth factor receptor 3.
[0193] In preferred embodiments, the gene editing payload is configured to edit the gamma globin locus of the patient's genome or the cell's genome. Preferably, the gamma globin promoter is edited to inhibit the recruitment of BCL11A. BCL11A is a potent repressor of the gamma globin gene, and thereby, inhibiting this binding reduces the repression of the gamma globin gene, mimicking the genetically persistent fetal hemoglobin (HPFH) mutations that occur naturally. Therefore, by targeting this region, persistent reactivation of fetal hemoglobin in the cell can be induced. In these embodiments, the gene editing payload preferably includes a CRISPR nuclease, e.g., Cas9, optionally SpCas9, and a gRNA having the sequence:CTT GTC AAG GCT ATT GGT CA (SEQ ID NO: 17) [9]. These embodiments are particularly preferred when the antibody is an anti-CD34 or anti-Gpr56 antibody. In alternative embodiments, the gene editing payload is configured to edit the hemoglobin β locus of the patient's genome or the cell's genome. In such embodiments, the payload preferably further includes a donor DNA strand containing a sequence or partial sequence of the wild-type hemoglobin β locus. Thus, the payload is configured to modify the hemoglobin β locus.
[0194] <Conjugation and Manufacturing Method> In embodiments of antibody-conjugated nanoparticles, the nanoparticles are preferably conjugated to the antibody in the antibody Fc region, i.e., in the antibody constant region.
[0195] In one embodiment, the nanoparticles and antibody are conjugated such that the antibody is randomly oriented on the surface of the nanoparticles. In a more preferred embodiment, the nanoparticles and antibody are conjugated such that the antibody is oriented so that the antigen-binding site faces away from the nanoparticle core, enabling optimal binding to the target molecule.
[0196] In one embodiment, nanoparticles are conjugated to the antibody via ester bonding to an amino group on the antibody. In one embodiment, the amino group is derived from a lysine residue in the antibody's Fc region. In one embodiment, the conjugation is by an NHS esterification reaction.
[0197] In one embodiment, nanoparticles are conjugated to the antibody via thioether bonding to a thiol group on the antibody. In one embodiment, the amino group is derived from a cysteine residue in the antibody's Fc region. In one embodiment, the cysteine residue is a C-terminal cysteine, i.e., the cysteine residue is located at the C-terminus of the Fc region. In one embodiment, the cysteine residue is located near the C-terminus of the Fc region, for example, within 20 residues of the C-terminus, for example, within 15, 10, 5, 4, 3, or 2 residues of the C-terminus. In one embodiment, the conjugation is by a maleimide-thiol reaction.
[0198] In one embodiment, the nanoparticles are site-specifically conjugated to the antibody, that is, the nanoparticles are conjugated to a specific residue of the antibody, for example, the C-terminal residue of the Fc region.
[0199] In one embodiment, the nanoparticles are conjugated to one or more antibody molecules. In one embodiment, the nanoparticles are conjugated to two or more antibody molecules, for example, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, or 40 or more antibody molecules. In one embodiment, the nanoparticles are conjugated to multiple antibody molecules.
[0200] In one embodiment, the nanoparticles are conjugated to an antibody molecule targeting one antigen; for example, the nanoparticles may be conjugated to only an anti-CD34 or anti-Gpr56 antibody molecule. In another embodiment, the nanoparticles are conjugated to antibody molecules targeting one or more different antigens; for example, the nanoparticles may be conjugated to both anti-CD34 and anti-Gpr56 antibody molecules. In one embodiment, the nanoparticles are conjugated to antibody molecules targeting two, three, four, five, six, seven, eight, nine, or ten or more different antigens. In this embodiment, the antigens preferably originate from the same target cell so that the nanoparticles target only one cell type. The nanoparticles may be further, or instead, conjugated to one or more bispecific or multispecific antibodies.
[0201] In a preferred embodiment, the nanoparticles are conjugated to one or more monoclonal antibody molecules. In this embodiment, each antibody molecule is identical, i.e., each antibody molecule conjugated to the nanoparticles shares the same sequence.
[0202] In one embodiment, the present invention provides a method for producing an antibody conjugate, which includes the following: A step of modifying the antibody heavy chain coding sequence to introduce a cysteine residue at or near the C-terminus of the heavy chain constant region. The step of generating a modified antibody from a modified sequence (the modified antibody contains a cysteine residue at or near the C-terminus of the heavy chain constant region, and the cysteine residue has a free thiol group that is not covalently bonded to another cysteine residue), The steps of obtaining poly(lactic acid-coglycolic acid) (PLGA) nanoparticles containing PEG, and The step involves conjugating the nanoparticles to the antibody via site-directed maleimide bonding (a cysteine residue at or near the C-terminus of the heavy chain constant region is covalently bonded to one or more PEG groups of the nanoparticles).
[0203] In one embodiment, the obtained nanoparticles further include an encapsulated payload. The payload may be any payload described herein, most preferably a gene editing payload.
[0204] In one embodiment, the obtained nanoparticles further contain poly(lactic acid-coglycolic acid) (PLGA).
[0205] In one embodiment, nanoparticles are obtained by a method comprising: dissolving PLGA in dichloromethane (DCM); adding a payload to the PLGA-DCM mixture and emulsifying it (optionally under sonication); dropping the emulsified mixture into an aqueous phase containing polyvinyl acetate (PVA) and sonicating the solution; and washing and recovering the nanoparticles containing the PLGA and encapsulated payload.
[0206] In one embodiment, the nanoparticles are freeze-dried. In another embodiment, the nanoparticles are rehydrated before conjugation to the antibody.
[0207] Alternatively or additionally, nanoparticles can be conjugated to antibodies using click chemistry. For example, nanoparticles can be conjugated to antibodies using one or more of the following reactions: copper(I) catalyzed azide-alkyne cycloaddition; strain-enhanced azide-alkyne cycloaddition; strain-enhanced alkyne-nitrone cycloaddition; alkene and azide[3+2] cycloaddition; reverse electron-demanded Diels-Alder reaction of alkene and tetrazine; photoclick reaction of alkene and tetrazole.
[0208] In some embodiments, nanoparticles are conjugated to antibodies via saltase-mediated peptide transfer (see, for example, Popp et al. Current Protocols in Protein Science 56(1):15.3.1-15.3.9).
[0209] <Pharmaceutical composition> The present invention further provides a pharmaceutical composition comprising the antibody and / or antibody-conjugate nanoparticles of the present invention.
[0210] In one embodiment, the pharmaceutical composition comprises an anti-CD34 antibody comprising a heavy chain variable region (VH) containing three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) containing three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 containing the amino acid sequence of SEQ ID NO: 1; HCDR2 containing the amino acid sequence of SEQ ID NO: 2; and HCDR3 containing the amino acid sequence of SEQ ID NO: 3; and VL comprises LCDR1 containing the amino acid sequence of SEQ ID NO: 4; LCDR2 containing the amino acid sequence of SEQ ID NO: 5; and LCDR3 containing the amino acid sequence of SEQ ID NO: 6.
[0211] In one embodiment, the pharmaceutical composition comprises an anti-Gpr56 antibody comprising a heavy chain variable region (VH) containing three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) containing three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 containing the amino acid sequence of SEQ ID NO: 9; HCDR2 containing the amino acid sequence of SEQ ID NO: 10; and HCDR3 containing the amino acid sequence of SEQ ID NO: 11; and VL comprises LCDR1 containing the amino acid sequence of SEQ ID NO: 12; LCDR2 containing the amino acid sequence of SEQ ID NO: 13; and LCDR3 containing the amino acid sequence of SEQ ID NO: 14.
[0212] In one embodiment, the pharmaceutical composition comprises an antibody conjugate including an anti-CD34 antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a payload. In some embodiments, the antibody is an HCAb.
[0213] In one embodiment, the pharmaceutical composition comprises an antibody conjugate including an anti-Gpr56 antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a payload. In some embodiments, the antibody is an HCAb.
[0214] In one embodiment, the pharmaceutical composition comprises an antibody conjugate including an antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a gene editing payload. In some embodiments, the antibody is an HCAb.
[0215] In one embodiment, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients. One or more pharmaceutically acceptable excipients may be selected from the list including: solvents, emulsifiers, carriers, anti-adhesion agents, binders, coatings, colorants, dyes, preservatives, buffers, isotonic agents, antioxidants, chelating agents, complexing agents, solubilizers, flocculants, suspending agents, wetting agents, and surfactants.
[0216] The pharmaceutical composition may additionally or alternatively contain one or more pharmaceutically acceptable diluents.
[0217] In one embodiment, the antibody or antibody conjugate of the pharmaceutical composition is lyophilized.
[0218] In one embodiment, the pharmaceutical composition further comprises one or more additional therapeutic agents, for example, one or more additional drugs. In one embodiment, the pharmaceutical composition further comprises one or more chemotherapeutic agents.
[0219] In one embodiment, the pharmaceutical composition is suitable for medical use in human patients.
[0220] In one embodiment, the pharmaceutical composition is formulated for intravenous, subcutaneous, intramuscular, subarachnoid, oral, sublingual, intraocular, ear drops, or cutaneous administration. Preferably, the pharmaceutical composition is formulated for intravenous use. In one embodiment, the pharmaceutical composition is formulated for direct administration to a tumor (e.g., a brain tumor).
[0221] <Treatment Method> The present invention further provides treatment methods including therapeutic applications of the antibody and / or antibody-conjugate nanoparticles of the present invention.
[0222] In one embodiment, a method is provided for treating or improving symptoms of a hereditary disorder, the method comprising the step of administering to a patient a composition comprising an antibody conjugate, the antibody conjugate comprising an antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a gene editing payload. Also provided is an antibody conjugate used for treating or improving symptoms of a hereditary disorder, comprising an antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a gene editing payload.
[0223] In one embodiment, a method is provided for treating or improving the symptoms of a disease, the method comprising the step of administering to a patient a composition comprising an antibody conjugate, the antibody conjugate comprising an anti-Gpr56 antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a therapeutic payload. Also provided is an antibody conjugate used for treating or improving the symptoms of a disease, comprising an anti-Gpr56 antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a therapeutic payload.
[0224] In one embodiment, a method is provided for treating or improving the symptoms of a disease, the method comprising the step of administering to a patient a composition comprising an antibody conjugate, the antibody conjugate comprising an anti-CD34 antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a therapeutic payload. Also provided is an antibody conjugate used for treating or improving the symptoms of a disease, comprising an anti-CD34 antibody and nanoparticles conjugated to the antibody, the nanoparticles comprising a therapeutic payload.
[0225] The therapeutic payload is any payload described herein, preferably a gene editing payload (optionally comprising a CRISPR nuclease). Most preferably, the payload is configured to edit the γ-globin locus of the patient's genome. Preferably, the γ-globin promoter is edited to inhibit the recruitment of BCL11A. In this embodiment, the gene editing payload preferably comprises a CRISPR nuclease, e.g., Cas9, optionally SpCas9, and a gRNA having the sequence:CTT GTC AAG GCT ATT GGT CA (SEQ ID NO: 17) [9].
[0226] When the therapeutic payload is a gene editing disorder, the antibody conjugate is preferably used in a manner that treats or improves the symptoms of the hereditary disorder. Preferably, the hereditary disorder is a blood disorder, such as a hematological malignancy, or an abnormal hemoglobin disorder, such as sickle cell disease (SCD) or β-thalassemia.
[0227] In one embodiment, the method includes administering the antibody conjugate intravenously, intrauterine, subcutaneously, intramuscularly, subarachnoidally, orally, sublingually, intraocularly, ear-instilled, or skin-borne. Preferably, the antibody conjugate is administered intravenously.
[0228] In one embodiment, an antibody conjugate used in a method for treating or improving a disease such as a genetic disorder is provided in a pharmaceutical composition, for example, any pharmaceutical composition described herein.
[0229] The methods disclosed herein enable in vivo treatment of diseases, such as genetic disorders, including in vivo delivery of gene-editing payloads, with minimized off-target effects. In particular, an antibody molecule(s) conjugated with nanoparticles targets the nanoparticle payload to target cells, and the payload is delivered exclusively or almost exclusively to the target cells. Preferably, the target cells are hematopoietic stem cells. The methods disclosed herein may instead be used for ex vivo treatment of diseases, such as in cell therapy.
[0230] In one embodiment, less than 10% of the total payload administered to the patient via antibody-conjugated nanoparticles, for example, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1%, is delivered to non-target cells.
[0231] The present invention also encompasses ex vivo methods for delivering a payload to target cells, for example, for delivering a gene editing payload to target cells. In one embodiment, a method for treating or improving symptoms of a disease, such as a genetic disorder, includes the steps of: removing autologous cells from a patient; applying antibody-conjugated nanoparticles containing a payload to autologous target cells; confirming delivery of the payload to one or more target cells (the payload is delivered if it is intracellular); and transplanting one or more target cells containing the delivered payload into the patient. In one embodiment, the autologous cells are autologous stem cells, such as autologous hematopoietic stem cells. In one embodiment, the payload is a gene editing payload. In one embodiment, payload delivery is confirmed by observing a dye, such as a fluorescent dye, within the target cells. In this embodiment, the payload includes a dye, such as a fluorescent dye, which can be conjugated to a therapeutic payload. In one embodiment, the fluorescent dye is DiD (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate).
[0232] The present invention further provides an ex vivo method for gene editing T cells, comprising the step of administering antibody-conjugate nanoparticles containing a gene editing payload in vitro to a population of cells containing T cells (e.g., a population of peripheral blood lymphocytes), wherein the antibody targets a T cell surface antigen (e.g., CD4, CD8, CD3, CTLA4, TCR, TCRα, or TCRβ). In some embodiments, the gene editing payload is capable of knocking out PD-1. In some embodiments, PD-1 knockout T cells are proliferated ex vivo and then administered to a patient (e.g., a cancer patient, e.g., a patient with esophageal cancer, bladder cancer, prostate cancer, renal cell carcinoma, or (non-small cell) lung cancer).
[0233] The present invention further provides a method for treating cancer in a patient, including: (a) A step of isolating a cell population containing T cells from the patient (optionally, the cell population is a peripheral blood lymphocyte population), (b) A step of administering antibody-conjugate nanoparticles containing a gene editing payload to a cell population in vitro (the antibody may target T cell antigens (e.g., CD4, CD8, CD3, TCR, TCRα, or TCRβ), and the gene editing payload may optionally knock out PD-1), and (c) A step in which gene-edited T cells are administered to the patient.
[0234] The present invention further provides an ex vivo method for gene editing hematopoietic stem cells (HSCs), comprising the step of in vitro administering antibody-conjugate nanoparticles containing a gene editing payload to a cell population containing HSCs (e.g., in a blood sample or bone marrow extract), wherein the antibody targets an HSC surface antigen (e.g., CD34, Gpr56, Gpr97, CD49, CD49f, CD90, CD117, or endomucin). In some embodiments, the gene editing payload is capable of repairing a gene defect in the HSCs. In some embodiments, the gene-edited HSCs are grown ex vivo and then administered to a patient (e.g., a patient with a genetic disorder resulting from a genetic defect, e.g., aplastic anemia, sickle cell disease, thalassemia, hemoglobinopathy, or severe combined immunodeficiency).
[0235] The present invention further provides a method for treating a patient's hereditary disorder, including: (a) A step of optionally isolating a cell population containing patient-derived HSCs from a blood sample or bone marrow extract. (b) A step of administering antibody-conjugate nanoparticles containing a gene editing payload to a cell population in vitro (the antibody targets an HSC surface antigen (e.g., CD34, Gpr56, Gpr97, CD49, CD49f, CD90, CD117, or endomucin), and optionally the gene editing payload can repair a genetic defect that causes a hereditary disorder), (c) A step in which the gene-edited HSC is administered to the patient.
[0236] The present invention further provides a method for treating or improving the symptoms of a disease, comprising the step of administering an anti-CD34 antibody to a patient, wherein the anti-CD34 antibody comprises a heavy chain variable region (VH) comprising three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) comprising three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; and HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; and VL comprises LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and LCDR3 comprising the amino acid sequence of SEQ ID NO: 6. The anti-CD34 antibody used for treating or improving the symptoms of a disease is also provided.
[0237] The present invention also provides a method for treating or improving the symptoms of a disease, comprising the step of administering an anti-Gpr56 antibody to a patient, wherein the anti-Gpr56 antibody comprises a heavy chain variable region (VH) comprising three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3), and a light chain variable region (VL) comprising three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3), wherein VH comprises HCDR1 comprising the amino acid sequence of SEQ ID NO: 9; HCDR2 comprising the amino acid sequence of SEQ ID NO: 10; and HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, and VL comprises LCDR1 comprising the amino acid sequence of SEQ ID NO: 12; LCDR2 comprising the amino acid sequence of SEQ ID NO: 13; and LCDR3 comprising the amino acid sequence of SEQ ID NO: 14. The anti-Gpr56 antibody used for treating or improving the symptoms of a disease is also provided.
[0238] In one embodiment, an anti-CD34 or anti-Gpr56 antibody is provided in a pharmaceutical composition as described herein. [Examples]
[0239] Herein, the present invention will be further illustrated by the following non-limiting embodiments.
[0240] [Example 1] The objective of this study was to provide PLGA-PEG nanoparticles that can specifically target hematopoietic stem cells. This was achieved by conjugating the nanoparticles with a novel anti-CD34 / anti-Gpr56 antibody.
[0241] <Expression patterns and hematopoietic capacity of Gpr56+ and CD34+ cells in human umbilical cord blood and peripheral blood> The expression patterns of CD34 and Gpr56 in human umbilical cord blood and peripheral blood were evaluated by flow cytometry (Figure 1A). 1–1.3% of viable (7AAD-) cells were found to be CD34-positive in peripheral blood and umbilical cord blood, respectively, while Gpr56 showed broader expression at 13–14.4%. Viable CD34 and Gpr56 cells were further analyzed for co-expression of CD34 and Gpr56. Analysis showed that 42% of CD34 cells in umbilical cord blood and 39% in peripheral blood co-expressed CD34 and Gpr56. In contrast, only a small fraction of Gpr56+ cells co-expressed CD34, at 0.5% in umbilical cord blood and 0.4% in peripheral blood.
[0242] To evaluate the hematopoietic capacity of CD34+ and Gpr56+ expressing cells in peripheral blood, Gpr56+, CD34+, CD34+Gpr56-, CD34+Gpr56+, and CD34-Gpr56+ populations were FACS-selected as described below (Figure 1A-B), followed by methylcellulose culture. The number and types of hematopoietic progenitor cell colonies were counted (Figure 1C). Colonies were detected in the CD34- population, but the number of hematopoietic colonies in the CD34+Gpr56+ population was 10-fold higher compared to colonies derived from the same number of CD34+ and Gpr56+ positive cells.
[0243] In summary, Gpr56 has a broader expression pattern than CD34, but approximately 40% of the CD34+ population co-expressed Gpr56. Therefore, hematopoietic capacity is significantly enhanced when the markers Gpr56 and CD34 are combined.
[0244] <Generation of novel, fully human α-Gpr56 and α-CD34 antibodies> To target human HSCs for clinical use, we generated fully human mAbs for common and novel HSC markers CD34 and Gpr56 using an H2L2 transgenic mouse model (Harbour) encoding a chimeric immunoglobulin with human variable heavy and light chains and a rat-derived constant region. For this purpose, a peptide covering the extracellular domain region 191aa–207aa of CD34 bound to keyhole limpet hemocyanin (KLH) was used as an antigen for immunizing six H2L2 mice. For Gpr56, a recombinant His-tagged soluble protein containing the extracellular domain was used as an antigen for immunizing another group of six H2L2 mice (Figure 2A). Over 5000 hybridomas were screened for each of two independent fusion experiments using antigen-specific ELISA. Fifteen CD34 peptide-specific hybridomas were selected using the same peptide bound to BSA for screening to exclude KLH-positive hybridomas. All 15 CD34-positive hybridomas were subcloned, sequenced, and prepared for further characterization. More than 70 hybridomas were Gpr56-positive. The supernatant was tested for binding affinity to Gpr56-expressing cell lines (Figure 7), and those with high affinity were subcloned, sequenced, and prepared for further characterization. Hybridoma clone 3.8g8 for Gpr56 and clone L5F1 for CD34 showed the best affinity to primary cells and were selected for recombinant fully human mAb production. The DNA encoding the variable regions of the heavy and light chains was cloned into expression plasmids containing the human IgG1 constant region and the human kappa light chain constant region, respectively (Harbour BioMed vectors pHBM000267 and pHBM000265). The IgG1 skeleton used contains the N297A mutation, which reduces antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). A variant was created in which an extra cysteine is added to the C-terminus of the Fc region (Figure 2B).Recombinant human L5F1 and 3.8g8 mAbs, as well as non-specific isotype control mAbs (anti-strep tag and anti-MSLN), were generated in HEK-293 free-style cells after transient co-transfection with two expression plasmids (encoding the appropriate combinations of heavy and light chains). After 7 days, the cells were centrifuged and the human antibodies were purified from the supernatant using protein A affinity chromatography. Recombinant expressed human 3.8g8 and L5F1 were verified by flow cytometry. Recombinant human L5F1 and 3.8g8 mAbs showed a similar expression pattern in umbilical cord blood as commercially available Gpr56 and CD34 antibodies (Figure 2C).
[0245] <Formulation of Gpr56 and CD34-targeted PLGA-PEG-NPs> To develop a carrier system that can be used to specifically target and deliver payloads to HSCs, PLGA-PEG-NPs encapsulating the fluorescent dye DiD were formulated using an o / w emulsion and solvent evaporation extraction method (Table 1 below). [Table 1]
[0246] To provide specificity for targeting HSCs, recombinant human L5F1 and 3.8g8 mAbs were conjugated to the surface of PLGA-NPs using two different conjugation strategies (Figure 3A). In Strategy 1, the primary amines present in the lysine residues of the mAbs were used. Lysine is abundant and widely distributed and is easily modified due to its reactivity and position on the surface of the mAb. In Strategy 2, the mAbs were conjugated with cysteine residues (Figure 3A). Cysteine is not as abundant as lysine and these cysteines form exclusive covalent disulfide bonds to stabilize the tertiary structure of the mAb and are therefore non-reactive under non-reducing conditions. By cloning a cysteine residue at the C-terminus of the heavy chain, an additional unpaired cysteine residue with a free thiol group in the heavy chain Fc region is obtained for site-specific conjugation to the NPs.
[0247] PLGA-NPs were functionalized with lipid-PEG(2000)-NHS and conjugated with mAbs via an N-hydroxysuccinimide (NHS) ester-mediated reaction (Strategy 1), or PLGA-NPs were functionalized with lipid-PEG(2000)-maleimide and conjugated with mAbs via a specific reaction between the maleimide group (PEG-maleimide) and the thiol (sulfhydryl group) (Strategy 2) (Figure 3B). In Strategy 1, any lysine residue can be used for conjugation, resulting in random orientation of mAbs on the PLGA-NP surface, while in Strategy 2, site-specific orientation of mAbs with the binding groove facing away from the NP core became possible. This enables optimal engagement with the target molecule.
[0248] DLS analysis determined the size of the PLGA-NPs to be 311–475 nm in diameter (Table 1), and the polydispersity index (PDI) values of 0.2–0.4 obtained from DLS measurements showed a uniform size distribution (Table 1). In addition, ZetaSizer measurements revealed a negative surface charge of the NPs (Table 1). In contrast to control NPs without a targeted area, the size of the NPs increased slightly with mAb conjugation (Table 1). TEM analysis confirmed the round shape of the NPs (Figure 3C). Confocal analysis of CD34-targeted PLGA-PEG-NPs confirmed the presence of recombinant human L5F1 mAb on the NP surface (Figure 3D).
[0249] <Binding of Gpr56 and CD34-targeted PLGA-PEG-NP in peripheral blood> To evaluate the specificity of targeted PLGA-PEG-NPs for CD34+ HSPCs in peripheral blood, and whether the conjugation strategy (and orientation) of mAbs to the NP surface affects binding efficiency, PBMCs derived from healthy hematopoietic cell donors were incubated at 37°C for 15 minutes with PLGA-PEG-NPs conjugated to anti-MSLN and anti-strep tagged control mAbs, as well as HSC-targeted mAbs anti-Gpr56 and anti-CD34 (all of which incorporate additional unpaired cysteine into the Fc tail of the Fc). Each mAb was conjugated via NHS-ester and maleimide coupling strategies (Table 1). The fluorescent dye DiD was co-encapsulated in the NPs.
[0250] CD34 is commonly used to mark HSPCs in blood and bone marrow. Therefore, after NP incubation, PBMCs were intensively washed and labeled with CD34 and viability dye 7AAD. NP binding was determined by measuring the percentage of DiD-positive cells within the viable CD34+ and CD34- cell populations (Figure 4A-B). CD34+ cells were efficiently targeted with anti-CD34-PLGA-PEG-NP, while only residual binding was observed in CD34- cells (Figure 4B).
[0251] Extensive analysis, including multiple blood cell donors, demonstrated efficient targeting of CD34+ HSPCs with both conjugation strategies using Gpr56- and CD34-PLGA-PEG-NP (Figure 4C), although 10–20% targeting was observed in the CD34- population with all mAbs (control and targeting). This is similar to the rate obtained with the control mAb. Using the maleimide conjugate strategy, the binding rate increased slightly. This suggests that the outward orientation of the mAb binding groove increased the binding of the antibody-conjugated PLGA-PEG-NP to CD34+ PBMCs.
[0252] Since Fc receptors are abundant in human blood cells, we evaluated their potential contribution to NP binding. To this end, binding studies were conducted in and out of the presence of an Fc receptor blocking reagent (Figure 4D). Pretreatment with the Fc receptor blocking reagent did not reduce the binding of targeted and control PLGA-PEG-NPs, regardless of the conjugation strategy. This suggests that nonspecific Fc receptor-mediated binding does not play a role in the binding of CD34- and gpr56-PLGA-PEG-NPs. Therefore, the 10-20% basal binding observed in CD34- cells and control PLGA-PEG-NPs may be a result of nonspecific mediated binding.
[0253] Next, the uptake kinetics of NPs coated with α-Gpr56, α-CD34, α-MSLN, or α-Strep mAb, conjugated via NHS-ester reaction or maleimide-thiol reaction, were determined (Figures 4E-F). PBMCs from one donor were incubated with PLGA-PEG-NP for up to 120 minutes. The percentage of CD34+ cells internalizing the fluorescent carrier was measured by flow cytometry. After 15 minutes, targeted PLGA-PEG-NP conjugated to mAb via maleimide-thiol reaction bound to significantly more CD34+ PBMCs than NP conjugated to mAb via NHS-ester reaction (Figure 4E) (Figure 4F). Uptake increased by 40-50% and 60-80% for NHS-ester conjugated and maleimide conjugated NPs, respectively. Binding of NPs conjugated to mAbs via maleimide reaction was significantly higher at all time points than that of control NPs conjugated to α-MSLN mAbs (Figures 4E-F).
[0254] Additional flow cytometry studies were conducted to analyze the binding and uptake behavior of CD34+ cells. For this purpose, CD34+ cells were incubated with PLGA-PEG-NPs at 4°C (where cells could bind to the NPs but not take them up) and under physiological conditions at 37°C for 1 hour (Figure 4G). After 1 hour, 40% of the targeted PLGA-PEG-NPs bound to the surface of CD34+ PBMCs, compared to less than 10% for the control NPs. Under physiological conditions, these values increased to over 60-70% for targeted PLGA-PEG-NPs and to approximately 20% for control NPs. Therefore, after 1 hour under physiological conditions, 20-30% of the targeted PLGA-PEG-NPs (values obtained at 37°C to 4°C) were taken up by CD34+ cells.
[0255] PBMCs represent a mixed cell population containing 1-2% CD34+ cells. Next, the binding of PLGA-PEG-NPs conjugated to α-Gpr56, α-CD34, and α-MSLN via the maleimide-thiol reaction to isolated CD34+ blood cells from PBMCs was evaluated. CD34+ cells were isolated from PBMCs using CD34+ magnetic beads and subsequently incubated with 10 μg / ml PLGA-PEG-NP. 51% and 68% of isolated CD34+ cells bound to PLGA-PEG-NP coated with α-Gpr56 or α-CD34 mAb, respectively, while 17% bound to PLGA-PEG-NP coated with α-MSLN and 21% bound to PLGA-PEG-NP coated with α-Strep (Figure 4H).
[0256] In summary, the data showed that CD34+ cells in PBMCs and isolated CD34+ cells specifically bound to PLGA-PEG-NP coated with targeted α-Gpr56 or α-CD34 mAb rather than PLGA-PEG-NP coated with control mAb. Conjugation of the antibody via a maleimide reaction using a free thiol group introduced into the Fc region slightly increased the uptake of targeted PLGA-PEG-NP.
[0257] <Uptake of α-Gpr56- and α-CD34-PLGA-PEG-NP by HSPC visualized with a confocal microscope> HSCs that regrow over the long term are quiescent cells, and their metabolism differs from that of other HSPC populations. These tiny cells, with very little cytoplasm, constitute only a fraction of all CD34+ cells. Efficient uptake by these cells is a requirement for the HSC delivery system. To confirm the intracellular localization of HSCs, whole PBMCs (Figure 5A) and isolated CD34+ cells (Figure 5B) were incubated for 1 hour with NPs coated with α-gpr56, α-CD34, and α-MSLN (conjugated via maleimidothiol) and analyzed by confocal microscopy.
[0258] Targeted α-Gpr56- and α-CD34-PLGA-PEG-NP bound and were readily taken up by CD34low-expressing cells exhibiting a typical nuclear structure of phagocytic cells. Nonspecific uptake of control α-MSLN-PLGA-PEG-NP was observed in several of these cells (Figure 8). Importantly, targeted α-Gpr56- and α-CD34-PLGA-PEG-NP were found to specifically bind to and be taken up by small, round CD34-high-expressing cells (HSCs) in PBMCs and isolated CD34+ cells, but not by control α-MSLN-PLGA-PEG-NP (Figures 5A-B).
[0259] <Uptake of α-Gpr56-PLGA-PEG-NP and α-CD34-PLGA-PEG-NP in different HSPC populations in peripheral blood> HSPC populations within the CD34+ pool of PBMCs can be distinguished by flow cytometry based on the expression of hematopoietic markers. Furthermore, depending on the potential of the hematopoietic lineage, corresponding metabolism, and differentiation state, they possess different uptake capabilities. Understanding the different uptake behaviors toward targeted α-Gpr56- and α-CD34-PLGA-PEG-NP is crucial for the specific delivery of therapeutic agents to HSPC populations. For this purpose, a nine-color flow cytometry panel and a sequential boolgating strategy were used according to the Clinical Laboratory Standards Institute (CLSI), enabling analysis of targeted and control PLGA-PEG-NP uptake within nine HSPC populations. PBMCs were incubated with 20 μg / ml of α-Gpr56-, α-CD34-, and α-Strep-PLGA-PEG-NP at 37°C for 15 minutes, followed by staining for flow cytometry. Dead cells were excluded by 7-AAD-positive staining. Monocytes and lymphocytes could be gated based on morphology within the CD45V population (Figure 6A). The HSC population could be narrowed down based on CD34+CD45low expression and its size / granularity.
[0260] Surviving CD34+ cells (CD34V) were further gated into CD34+CD38-, CD10+CD38- (common lymphoid progenitor cells, CLP), and CD10-CD38+ populations. Next, the CD34+CD38- event was further subdivided into pluripotent progenitor cells (MPP) and true HSC populations, defined as CD34+CD38-CD90-CD45RA- and CD34+CD38-CD90+CD45RA-, respectively. CD10-CD38+ cells could be further divided into CD135+CD45RA- (myeloid common progenitor cells, CMP), CD135+CD45RA+ (granulocyte-macrophage progenitor cells, GMP), and CD135-CD45RA- (megakaryocyte-erythrocyte progenitor cells, MEP). The proportion of NP(DiD)-positive cells was analyzed within each HSPC population (Figure 6B).
[0261] Analysis of the HSPC population showed efficient targeting of HSCs (about 60%) using α-Gpr56- and α-CD34-PLGA-PEG-NPs, as well as residual binding of the control α-Strep-PLGA-PEG-NPs (about 10-20%). Using both α-Gpr56- and α-CD34-PLGA-PEG-NPs, all other HSPC populations were targeted up to about 40%. Monocytes are well known to efficiently take up NPs. Thus, it was found that 60% of monocytes had taken up α-Gpr56- and α-CD34-PLGA-PEG-NPs. In contrast, lymphocytes, which express very low levels of CD34 and are non-phagocytic, were not efficiently targeted.
[0262] The materials and methods used in this study are described in further detail below.
[0263] <Materials> For the preparation of nanoparticles (NPs), dichloromethane (DCM) and dimethylformamide (DMF) were purchased from Sigma-Aldrich® (Zwijndrecht, the Netherlands). Poly(D,L-lactic-co-glycolic acid) 50:50 (PLA / PGA) and polyvinyl alcohol (PVA) were purchased from Sigma-Aldrich. DiD was purchased from ThermoFisher (Waltham, MA, USA). PEG-DSPE-200 and PEG-DSPE-maleimide were purchased from Sigma Aldrich.
[0264] In the methylcellulose assay, MethoCult™ H4434 Classic medium was purchased from STEMCELL Technologies (Vancouver, Canada).
[0265] In flow cytometry, cells were stained with anti-CD10-FITC (clone HI10a), anti-CD135-PE (clone BV10A4H2), anti-CD45RA-APC-Cy7 (clone HI100), anti-gpr56-PE (clone CG4) (all obtained from BioLegend, California, USA), anti-CD34-PE-Cy7 (clone 581), CD90 OptiBuild BV711 (clone 5E10), anti-CD38 BD Horizon V450 (clone HIT2), anti-CD45 BD Horizon V500 (clone HI30) (all obtained from BD biosciences), and 7-AAD (Invitrogen). Fc receptors were blocked with an anti-human FcR blocking reagent (Miltenyi Biotec, Bergiggradibach, Germany).
[0266] For microscopic examination, cells were stained with anti-CD34 antibody (clone 561, BioLegend) and detected with secondary goat anti-mouse IgG(H+L)-Alexa Fluor 488 antibody (Invitrogen, ThermoFisher Scientific).
[0267] <Antibody generation> Generation of mAbs 3.8g8 (α-Gpr56), L5F1 (α-CD34), 1.2e8 (α-mesothelin (MSLN)), and 1.15f2 anti-streptococcal tag monoclonal antibodies (mAbs):
[0268] Six H2L2 transgenic mice were immunized with a CD34-specific peptide conjugated to keyhole limpet hemocyanin (LEQNKTSSCAEFKKDRG [SEQ ID NO: 18]) using Genscript. The human Gpr56 extracellular domain (ECD) was cloned into a pCAG hygro G2 vector after removing the G2 constant region, expressed as a his-tagged fusion protein in HEK293 cells, purified using Ni-NTA agarose beads, and used to immunize six H2L2 transgenic mice. For the initial injection, a freshly prepared stimulating adjuvant (Prionics) was used according to the manufacturer's instructions, and the antigen was injected at a dose of 20 μg / mouse, while a boost was performed using the Ribi(Sigma) adjuvant. Injections were administered subcutaneously at 2-week intervals, with the final boost performed intraperitoneally. Serum was tested after the third and sixth injections using antigen-specific ELISA. Four days after the final intraperitoneal injection, the spleen and lymph nodes were harvested, and hybridomas were constructed using a standard method with the SP 2 / 0 myeloma cell line (ATCC#CRL-1581) as the fusion partner. A total of over 10,000 hybridomas from both experiments (CD34 and Gpr56) were screened using antigen-specific ELISA.
[0269] <Antigen-specific ELISA for serum and hybridoma supernatant> ELISA was performed in a 96-well plate (Nunc® MaxiSorp®). 5 μg / ml of antigen in PBS was used for coating at room temperature (RT) for 2 hours. The antigen used for CD34 was the same peptide used for immunization, but conjugated to BSA, and the antigen for Gpr56 was the same protein used for immunization. Each well was blocked at room temperature for 30 minutes with 300 μl of PBS / 1% BSA / 1% nonfat milk powder and 0.1% Tween-20, and then the plate was washed three times with wash buffer (PBS / 0.1% Tween-20). To test the titer of antibodies in serum, 3 μl of serum was diluted with 600 μl of PBS / 1% BSA / 1% nonfat milk powder / 0.1% Tween-20, followed by dilutions of 1:1000, 1:3000, 1:7500, 1:15000, 1:30000, 1:60000, and 1:120000.
[0270] For blood ELISA, 50 μl of each serum diluent or 50 μl of hybridoma supernatant was added to each well and incubated at RT for at least 2 hours or overnight at 4°C.
[0271] After washing the plates five times with washing buffer, 50 μl each of horseradish peroxidase-labeled mouse anti-rat IgG antibody (Absea), diluted 1:2000, was added with blocking solution (clones KT148 anti-IgG1, KT98 anti-IgG2b, and KT99 anti-IgG2c were mixed together). After incubation at RT for 2 hours, the plates were washed five times with washing buffer, and 50 μl of POD substrate (Roche, BM Blue POD substrate soluble, #11484281001) was added. After 3-5 minutes, 50 μl of 1 M H2SO4 was added to stop the reaction, and absorption was measured at 450 nm (relative to a reference wavelength of 690 nm). For all positive hybridomas, a separate ELISA assay was performed to determine the isotype using each mouse anti-rat IgG secondary antibody individually.
[0272] Hybridoma supernatants were also tested by FAC analysis in CD34 and Gpr56 expressing cell lines, and those with the highest affinity (3.8g8 and LF51, Figures 9 and 10) were selected for subcloning and sequencing. For this purpose, non-essential amino acids 100×NEAA, Biowhittaker Lonza, catalog no. BE13-114E were added, and the subcloned hybridomas were cultured in serum and protein-free medium for hybridoma culture (PFHM-II (1×), Gibco). H2L2 antibodies were purified from the hybridoma culture supernatant using protein G affinity chromatography (Temecula, California, catalog no. N16-266). The purified antibodies were stored at 4°C until use.
[0273] Hybridoma sequencing was performed according to the Harbour protocol for H2L2 mice.
[0274] For recombinant human mAb production, the variable regions of the heavy and light chains were cloned into expression plasmids containing the constant regions of the human IgG1 heavy chain and Ig kappa light chain, respectively (HarbourBioMed vectors pHBM000267 and pHBM000265). Both plasmids contained a mouse Igκ reader sequence that enabled efficient secretion of recombinant antibodies. Recombinant human Abs3.8g8 (anti-Gpr56), L5F1 (anti-CD34), and anti-strep-tagged Abs and anti-MSLN, used as isotype controls, were produced in HEK-293T cells after simultaneous transfection with two expression plasmids encoding the appropriate IgG1 heavy and κ light chains. Human antibodies were purified from the cell culture supernatant using protein A affinity chromatography and eluted with 3M KSCn. Amicon filters with a cutoff of 30kD were used for PBS buffer exchange and sample concentration. The concentration was measured using nanodrops (280 nm), and the antibody was run under reducing and non-reducing conditions, and under SDS-Page. The purified antibody was stored at 4°C until use. Mice were immunized according to the protocol approved by the Dutch Committee on Laboratory Animals, DEC Nr EUR 1944.
[0275] <Preparation of PLGA-NP> NP encapsulating DiD fluorescent dye was prepared using an o / w emulsion and solvent evaporation extraction method [10, 11]. Briefly, 90 mg of PLGA in 3 mL of DCM containing 3 mg of DiD was dropped into 25 mL of aqueous 2% (w / v) PVA and emulsified for 90 seconds using an ultrasonic processor (Branson, sonofier 250). The lipid combinations (DSPE-PEG(2000)-maleimide (8 mg) and DSPE-PEG2000 (8 mg) or (DSPE-PEG(2000)-NHS (8 mg) and DSPE-PEG2000 (8 mg)) were dissolved in DCM and added to the vial. DCM was removed by a stream of nitrogen gas. Subsequently, the emulsion was quickly added to the vial containing the lipid and the solution was homogenized by 30 seconds of ultrasonication. After the solvent was evaporated overnight at 4°C, PLGA-NP was collected by ultracentrifugation (60000 g) for 30 minutes, washed three times with distilled water, and lyophilized.
[0276] <Antibody Conjugate> 1 mg of PLGA-PEG-DSPE-maleimide-NP was resuspended in PBS and 50 μg of recombinant mAb was added. The mixture was incubated overnight at 4°C or for 1 hour at room temperature with constant stirring in a tube rotator. Excess mAb was removed by centrifugation at 25000 g for 30 minutes. The reactive maleimide groups on the NP surface were quenched by adding free thiol (cysteine) at the end of the reaction, followed by two washing steps with PBS.
[0277] <Physicochemical Property Evaluation of Antibody-Coated PLGA-NP> The Z-mean size, polydispersity index (PDI), and zeta potential of antibody-coated PLGA-PEG-NPs were measured using a Malvern ZetaSizer 2000 (Malvern, UK; software: ZetaSizer 7.03). A fixed scattering angle of 90° at 633 nm was set for analysis. DLS and zeta potential measurements were performed on PLGA-NPs newly coated with mAbs.
[0278] <Transmission Electron Microscopy> The size and shape of NPs were characterized by transmission electron microscopy (TEM). Since organic samples such as PLGA-NPs have low electron density, negative staining was performed first to enhance contrast. For this purpose, PLGA-NPs coated with 3 μl of antibody reconstituted in water (3 mg / ml) were deposited onto a carbon-coated grid. The PLGA-PEG-NPs were allowed to precipitate for approximately 1 minute, blot-dried, and then coated with one drop of 2.3% uranyl acetate. After 1 minute, this drop was also blot-dried, and the sample was ready for TEM analysis. Analysis was performed using a Tecnai 12 Biotwin (FEI, Oregon, USA).
[0279] <Cell culture> Jurkat cells, 32D cells, and 32D-gpr56 cells were cultured in RPMI-1640 medium supplemented with 10% FCS and 1% Pen / Strep. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy buffy coat donors (Sanquin blood bank) by density centrifugation using Ficoll and used directly in targeting experiments.
[0280] <Flow Cytometry> Isolated controls and NP-treated PBMCs were resuspended in FACS buffer (2.5 g BSA in 500 ml PBS, 0.02% sodium azide) containing a 7-color panel of antibodies against hematopoietic stem and progenitor cell markers (HSPC) (CD10, CD135, CD45RA, CD34, CD90, CD38, CD45) and the viability dye 7AAD. Only live cells were included for analysis. Monocytes and lymphocytes could be gated based on morphology within the CD45+ population. HSCs were CD34+CD45low CD38-CD90+CD45RA-, and multipotent progenitor cells (MPPs) were CD34+CD45low CD38-CD90-CD45RA-.
[0281] CD34+CD45low CD38+CD10+ events were common lymphoid progenitor cells (CLPs). The CD38+CD10- population included myeloid common progenitor cells (CMPs, CD34+CD38+CD135+CD45RA-), granulocyte-macrophage progenitor cells (GMPs, CD34+CD38+CD135+CD45RA+), and megakaryocyte-erythroid progenitor cells (MEPs, CD34+CD38+CD135-CD45RA-). The BD LSR-II was used to assess the percentage of NP-positive cells within different HSPC populations. NP uptake was evaluated by measuring the percentage of DiD-positive cells within each subpopulation compared to control cells.
[0282] <NP Uptake Experiment> To evaluate NP binding and uptake into PBMCs, cells were washed and resuspended at 0.5 x 106 / 500 μl in IMDM medium and incubated with 20 μg / ml of the antibody-conjugated PLGA-PEG-NP at 37 °C for 15 minutes. Cells were washed three times with 10 ml of PBS and subsequently analyzed by flow cytometry. Live blood cells (7-AAD-) were gated as CD34+ and CD3- cells or the HSPC populations were further analyzed using the markers CD10, CD135, CD45RA, CD34, CD90, CD38, CD45. The percentage of NP (DiD)-positive cells was evaluated within each population.
[0283] To analyze the proportion of NPs bound to PBMCs after they were incorporated, the PBMCs were washed, resuspended in IMDM medium at 0.5 x 10⁶ / 500 μl, and incubated with 20 μg / ml antibody-conjugated PLGA-PEG-NPs at 37°C (incorporation and binding) or 4°C (binding) for 60 minutes. The cells were washed three times with cold PBS and subsequently analyzed by flow cytometry.
[0284] Isolated CD34+ cells were washed and incubated with 20 μg / ml antibody-conjugated PLGA-PEG-NP at 37°C for 15 minutes. Subsequently, the cells were washed three times with PBS and analyzed by flow cytometry.
[0285] <Confocal microscopy> The uptake of antibody-conjugated PLGA-PEG-NP by PBMCs and isolated CD34+ cells was analyzed by confocal microscopy. For this purpose, PBMCs were incubated with 40 μg / ml antibody-conjugated PLGA-PEG-NP at 37°C for 1 hour, followed by washing with PBS. The cell membrane was labeled with 10 μg / ml anti-CD34 primary antibody and then detected with a secondary antibody. After labeling, cells were seeded at room temperature for 15 minutes on coverslips coated with 100 μg / ml poly-L-lysine (Sigma Aldrich). Finally, cells were labeled with DAPI in RT for 5 minutes, fixed with 1% PFA for 15 minutes, and embedded in a mounting medium (Sigma Aldrich) containing Mowiol and Dabco. Fluorescence imaging was performed using an SP5 confocal microscope (Wetzlar, Germany) with a 63x oil objective lens.
[0286] <Methylcellulose> As described above, a methylcellulose colony formation assay was performed
[12] . PBMCs were stained with CD34 or Gpr56, or double-stained with CD34 and Gpr56, and different populations of CD34 and Gpr56-expressing cells were sorted using BD Aria-1. The sorted cells were centrifuged and resuspended in IMDM medium. 700 sorted cells per dish were seeded three times in 3.6 ml of methylcellulose containing 1% PS (1 mL per dish, H4434, StemCell Technologies) and incubated at 37°C and 5% CO2 for 14 days. Colonies were characterized and counted by bright-field microscopy.
[0287] [Example 2] The objective of this study was to investigate the ability of PLGA nanoparticles (NPs) to deliver the CRISPR-Cas9 gene editing system to cells. CRISPR-PLGA-NPs were successfully synthesized and readily taken up by HUDEP-2 cells, primary erythroblasts, and CD34+ cells, demonstrating non-toxicity and a significant increase in HbF levels. The development of CRISPR-PLGA-NPs to increase HbF levels in erythroid cells expands the toolbox of CRISPR delivery vehicles targeting HSPCs for the treatment of hemoglobinopathy and other genetic disorders.
[0288] <Material> For the preparation of NP, dichloromethane (DCM) and dimethylformamide (DMF) were purchased from Sigma-Aldrich® (Zwijndrecht, Netherlands). Poly(D,L-lactic acid-coglycolic acid) 50:50 (PLA / PGA), polyvinyl alcohol (PVA), calcium nitrate (Ca(NO3)2), and diammonium hydrogen phosphate (NH4)2HPO4 were purchased from Sigma-Aldrich. Cy5 acid was purchased from Kerafast (Boston, USA). Alt-R® Cas9 nuclease V3 (S. pyogenes), Alt-R® CRISPR-Cas9 crRNA, Alt-R® CRISPR-Cas9 tracrRNA, Alt-R® CRISPR-Cas9 tracrRNA-ATTO® 550, and nuclease-free water were purchased from Integrated DNA Technologies (IDT) (Iowa, USA). Chemically modified sgRNA was purchased from Biolegio (Nijmegen, Netherlands). Lipofectamine® CRISPRMAX® Cas9 transfection reagent was purchased from ThemoFisher Scientific (Massachusetts, USA).
[0289] For cell culture, StemSpan and MethoCult® H4434 Classic medium were purchased from STEMCELL Technologies (Vancouver, Canada). EPO Eprex (1000IE) was purchased from Janssen-Cilag AG (Zug, Germany). Human recombinant SCF was purchased from BioLegend (San Diego, USA). Dexamethasone, SyntheChol, and doxycycline were purchased from SigmaAldrich.
[0290] For flow cytometry, cells were stained with anti-HbF-FITC (clone REA533; Miltenyi Biotec, Bergig-Graddibach, Germany), anti-GPA (clone HIR2; BioLegend, BioLegend, California, USA), and anti-CD71 (clone CY1G4, BioLegend). Non-conjugate antibodies were detected with the secondary antibody goat anti-mouse IgG(H+L)-Alexa Fluor 488 (Invitrogen, ThermoFisher Scientific). For confocal microscopy, cells were stained with anti-GPA (BioLegend), anti-Cas9 (clone 7A9, BioLegend), anti-CD34 (clone 561, BioLegend), and anti-EEA-1 (polyclonal, Invitrogen, ThermoFisher Scientific). The secondary antibodies were donkey anti-rabbit Alexa-Fluor 488 and goat anti-mouse IgG1 Alexa-Fluor 488, while the secondary antibodies were goat anti-mouse IgG2a Alexa-Fluor 488 and anti-mouse IgG1 Alexa-Fluor 568 (Invitrogen, ThermoFisher Scientific). Lysosomes were labeled with LysoTracker® Green (Invitrogen, ThermoFisher Scientific).
[0291] <grna> The sgRNA (Biolegio) was purchased as an oligonucleotide. eGFP-targeting sgRNA: GGG CGA GGA GCU GUU CAC CG; sgRNA-2[9]: CTT GTC AAG GCT ATT GGT CA; Scrambled sgRNA (Biolegio): CCCGCUCCUCGACAAGUGGC.
[0292] <Preparation of CRISPR / Cas9-PLGA nanoparticles> CRISPR / Cas9-PLGA-NP was synthesized according to the oil-in-water (W1 / O / W2) double emulsion solvent evaporation method [10,11] (Figure 11B). Before synthesis, beakers, spatulas, sonicator tips, and magnetic stirrers were washed, contaminants were removed with RNAse-zap solution, and rinsed with RNAse-free water. First, a complex of Cy5 dye and Cas9 protein was prepared (1). For this purpose, 0.1 mg of Cy5 (acidic) dye was dissolved in 40 μl of RNAse-free water, and then 66 μg of Cas9 was added. The mixture was incubated at room temperature (RT) for 30 minutes. Next, a calcium phosphate solution was prepared to precipitate the gRNA (2). For this purpose, a previously reported rapid precipitation method was modified
[13] . Two pipettes were prepared, one containing 105 μl of aqueous calcium nitrate (6.25 mM) and the other containing 105 μl of aqueous diammonium hydrogen phosphate (3.74 mM). Both solutions were pipetted simultaneously and mixed on a paraffin sheet. The resulting calcium phosphate solution was added dropwise, while vortexing, to an Eppendorf tube containing 12.8 μg of sgRNA or a hybridized crRNA-tracer RNA complex (according to the IDT user manual) in 40 μl of duplex buffer. The sgRNA and salt mixture was cooled on ice for 5 minutes. In the next step, calcium phosphate-CRISPR / Cas9-PLGA-NP was synthesized: 10 mg of PLGA was dissolved in 750 μl of DCM (3). First, 210 μl of calcium phosphate and gRNA prepared in step 2 were added. Next, 40 μl of the Cy5-Cas9 complex prepared in step 1 was added. A mixture of calcium phosphate-gRNA, Cy5-Cas9, and PLGA-polymer was immediately emulsified by sonication (Sonifier 250, ultrasonic tip, Branson, Connecticut, USA) using the following settings: sonication time of 60 seconds, constant duty cycle, power control: 4. The mixture was kept on ice during sonication. Immediately after sonication, the W1 / O phase was added dropwise to an aqueous phase (3000 μl) containing 30 mg of emulsifier PVA. Before use, the PVA aqueous phase was dissolved in an 80°C water bath for 20 minutes and cooled to room temperature.As described above, the solution was immediately sonicated. After sonication, DCM was removed under reduced pressure (200 - 600 mbar) using a rotary evaporator for about 2 minutes, and excess PVA was removed by centrifugation (at 4 °C, 14,800 rpm for 15 minutes). After centrifugation, the NPs were washed three times with 1000 μl of RNase - free water and then lyophilized. All washing solutions were saved to measure the loading efficiency of Cas9, Cy5, and gRNA. The NPs were stored at - 80 °C and rehydrated before use.
[0293] <Characterization of the Physicochemical Properties of CRISPR / Cas9 - PLGA - NPs> The Z - average size, polydispersity index (PDI), and zeta potential of CRISPR / Cas9 - PLGA - NPs were measured using a Malvern ZetaSizer 2000 (Malvern, UK; software: ZetaSizer 7.03). For the analysis, a fixed scattering angle of 90° at 633 nm was set. DLS and zeta potential measurements were performed on CRISPR / Cas9 - PLGA - NPs resuspended in RNase - free water before lyophilization.
[0294] <Transmission Electron Microscopy> Furthermore, the size, shape, and uniformity of the NPs were characterized by transmission electron microscopy (TEM). Since organic samples such as PLGA - NPs have low electron density, negative staining was first performed to enhance the contrast. For this purpose, 3 μl of CRISPR / Cas9 - PLGA - NPs reconstituted with RNase - free water (3 mg / ml) was deposited on a carbon - coated grid. The CRISPR / Cas9 - PLGA - NPs were allowed to precipitate for about 1 minute, blotted dry, and then covered with one drop of 2.3% uranyl acetate. After 1 minute, this drop was also blotted dry, and the sample was ready for TEM analysis. The analysis was performed on a Tecnai 12 Biotwin (FEI, Oregon, USA).
[0295] <Quantification of the Loading Efficiency into CRISPR / Cas9 - PLGA - NPs> The loading efficiency of Cy5 into CRISPR / Cas9-PLGA-NPs was indirectly determined by quantifying Cy5 in the supernatant of the washing step collected during NP preparation, plotted against a Cy5 standard curve of known concentration using a spectrofluorometer.
[0296] To quantify the amount of encapsulated gRNA, CRISPR / Cas9-PLGA-NPs encapsulating Cas9 and hybridized gRNA consisting of crRNA and Atto550-labeled tracerRNA were prepared. The loading efficiency of gRNA into CRISPR / Cas9-PLGA-NPs was indirectly determined by quantifying the gRNA content in the supernatant of the washing step collected during NP preparation. Using a spectrofluorometer, the supernatant and a standard curve of crRNA-tracerRNA-Atto550 of known concentration were measured.
[0297] The loading efficiency of Cas9 into CRISPR / Cas9-PLGA-NPs was determined by nanodrop measurement. For this purpose, the amount of Cas9 protein in the supernatant of the washing step collected during NP preparation was quantified. For each batch of NPs (10 mg of PLGA), 66 μg of Cas9 was added during synthesis. Since the Cas9 concentration in the supernatant recovered in the washing step was low, first, all the supernatants were pooled and concentrated to a volume of 100 μl using an Amicon® Ultra-2 centrifugal filter (Sigma Aldrich) with a molecular weight cut-off of 100,000 kDa. The concentrated wash was measured using a nanodrop at 280 nm and blanked against the wash of control NPs synthesized without the addition of Cas9. The successful encapsulation of Cas9 was further confirmed by SDS and Western blot analysis of CRISPR / Cas9-PLGA-NPs hydrolyzed overnight with 0.8 M NaOH at 37 °C.
[0298] <In vitro release kinetics of Cas9 and gRNA> To track the release of Cas9 and gRNA in vitro, CRISPR / Cas9-PLGA-NPs encapsulating Cas9 and gRNA-Atto550 were resuspended in PBS at a concentration of 3.5 mg / ml. 300 μl of the NP solution (three times each) were placed in Eppendorf tubes and incubated on a heating block at 37°C in shaking mode (400 rpm). At the indicated time points (0, 1, 2, 4, 6, 24, 48, 72, 96, 6, 10, 15, 20, 25, and 30 days), 150 μl of the sample was removed and replaced with 150 μl of fresh PBS. After collecting the final time points, the amount of released gRNA was first quantified by measuring the sample and gRNA-Atto550 standard curve using a spectrophotometer. Next, the sample was concentrated to a volume of 20 μl using an Amicon® Ultra-2 centrifugal filter, and the amount of Cas9 released was measured by nanodrop measurement.
[0299] The cumulative release amount was calculated according to equation (1). E(%)=(VEΣ1n-1Ci+V0Cn) / m0×100 (1) E(%) is the cumulative release volume, VE is the recovered volume (150 μl), V0 is the starting volume, Ci and Cn are the concentrations of Cas9 and gRNA, i and n are the sampling times, and m0 is the total amount of CRISPR / Cas9-PLGA-NPs carrying Cas9 or gRNA.
[0300] <Cell culture> As previously described, human umbilical cord blood-derived erythrocyte progenitor cells 2 (HUDEP-2) were cultured
[14] . In summary, HUDEP-2 cells were cultured in StemSpan (Stem Cell Technologies) serum-free expansion medium supplemented with 1 μM dexamethasone, 1 μg / ml doxycycline, 50 ng / ml human SCF, 2 units / ml EPO, 0.4% SyntheChol, and 1% penicillin-streptomycin. Differentiation of HUDEP-2 cells was initiated by removing doxycycline, dexamethasone, and SCF, and increasing EPO to 10 units / ml. HUDEP-2-eGFP-expressing cells were generated by lentiviral transduction of HUDEP-2 cells using the pRRL-CMV-GFP plasmid (MJWERabelink, donated by LUMC). One week after transduction, eGFP-highly expressing HUDEP-2 cells were sorted using a FACSARIA I flow cytometer in BD (New Jersey, USA), and the majority of eGFP-expressing cells were further proliferated. As a positive control, gRNA / Cas9 RNP complexes were delivered to WT HUDEP-2 cells by electroporation using a Neon transfection system (ThermoFisher Scientific). The following settings were used during electroporation: 1600V, 10ms, 3 pulses. Electroporated HUDEP-2 cells were proliferated and used as a control.
[0301] Peripheral blood mononuclear cells (PBMCs) were obtained from healthy buffy coat donors (Sanquin Blood Bank) and cultured according to a three-phase erythroid differentiation protocol in StemSpan serum-free growth medium supplemented with 1 μM dexamethasone, 50 ng / ml human SCF, 2 units / ml EPO, 0.4% SyntheChol, and 1% penicillin-streptomycin [15, 16]. In phase 1 (days 1 - 7), 1 ng / ml human interleukin (IL)-3 (BioLegend) and 40 ng / ml human insulin-like growth factor I (IGF) (BioLegend) were included. Phase 2 (days 8 - 12) contained the same medium except that IL-3 and IGF1 were removed. Erythroid differentiation was monitored by flow cytometry using anti-CD71 and anti-GPA antibodies.
[0302] <CRISPR / Cas9-PLGA-NP-mediated gene editing> 1×10 5 1 × 10 individual HUDEP-2 cells were resuspended in 100 μl of StemSpan medium (containing supplements) and seeded into 96-well (flat-bottom) plates. Lyophilized CRISPR / Cas9-PLGA-NPs were resuspended in RNAse-free water at 5 mg / ml and immediately further diluted in StemSpan medium. CRISPR / Cas9-PLGA-NPs were always stored on ice. 100 μl of CRISPR / Cas9-PLGA-NP was added to 100 μl of HUDEP-2 cells to achieve final concentrations of 200 μg / ml, 100 μg / ml, 50 μg / ml, 25 μg / ml, or 12.5 μg / ml. HUDEP-2 cells were incubated with CRISPR / Cas9-PLGA-NP or control NPs at 37 °C for 24 h, then washed with medium to remove excess NPs and resuspended in fresh medium. NP-treated HUDEP-2s were cultured until 21 days after NP treatment. Cells were split and the medium was refreshed every 3 days. At the designated time points, cells were harvested for flow cytometry and RNA analysis. Samples were prepared in triplicate.
[0303] Using the erythrocyte differentiation protocol, primary erythroblasts were edited at the end of Phase 1. On day 8, when the cell culture was grown with erythrocyte progenitor cells, the cells were collected as described above and 1 × 10⁶ cells were harvested. 5 The cells were resuspended in 100 μl of Phase II medium, plated into 96-well (flat-bottom) plates, and treated with 200 μg / ml, 100 μg / ml, 50 μg / ml, 25 μg / ml, or 12.5 μg / ml of CRISPR / Cas9-PLGA-NP or control NP. The cells were grown and cultured in Phase II medium until day 21. At the specified time points, the cells were harvested for flow cytometry and RNA analysis.
[0304] <Flow Cytometry> HUDEP-2 cells, primary erythroblasts, or isolated CD34+ cells were collected and washed with PBS. To assess cell viability after NP treatment, cells were resuspended in FACS buffer containing Hoechst (2.5 g BSA and 0.02% sodium azide in 500 ml of PBS). The percentage of Hoechst-positive / negative cells was assessed using a BD LSR-II equipped with a UV laser. NP uptake was assessed by measuring the percentage of Cy5-positive cells compared to untreated control cells.
[0305] To measure HbF expression in HUDEP-2 cells or primary erythroblasts, cells were fixed, permeabilized, and stained using an intracellular labeling kit (Inside Stain Kit, Miltenyi Biotec) and an anti-HbF-Fitc antibody (Miltenyi Biotec) according to the manufacturer's instructions for use.
[0306] <Confocal microscopy> The uptake and intracellular routing of CRISPR / Cas9-PLGA-NP in HUDEP-2 cells were analyzed by confocal microscopy. For this purpose, HUDEP-2 cells were incubated with 200 μg / ml of CRISPR / Cas9-PLGA-NP at 37°C for 1, 4, and 24 hours, followed by washing with PBS. The cell membrane was labeled with 10 μg / ml of anti-GPA primary antibody and then detected with a secondary antibody. After labeling, the cells were fixed with 4% paraformaldehyde in PBS at room temperature for 15 minutes, washed, and permeabilized with 0.1% Triton in PBS for 5 minutes. Intracellular labeling was performed by incubating the cells with 10 μg / ml of anti-EEA-1 or anti-Cas9 antibody, followed by conjugation with a secondary antibody during incubation. The cells were washed and seeded on coverslips coated with 100 μg / ml of poly-L-lysine (SigmaAldrich) at RT for 15 minutes. Finally, cells were labeled with DAPI in RT for 5 minutes, fixed with 1% PFA for 15 minutes, and embedded in a mounting medium (SigmaAldrich) containing Mowiol and Dabco. To label lysosomes, cells were thoroughly washed and incubated with green lysotracker (ThermoFisher Scientific) for 30 minutes at 37°C before labeling the cell membrane. Fluorescence imaging was performed using an SP5 confocal microscope (Wetzlar, Germany) with a 63x oil objective lens.
[0307] <rt-qpcr> Edited HUDEP-2 and control cells were washed with PBS and lysed in cell culture plates using TRIzol (Invitrogen, Grand Island, New York, USA). Total RNA content was isolated according to the manufacturer's protocol. Reverse transcription was performed using M-MLV Reverse Transcriptase (Promega, Madison, Wisconsin, USA). Expression levels of GAPDH, EGFP, HBB, and HBG were analyzed using real-time quantitative PCR. All real-time PCR reactions were performed using Biorad's real-time PCR detection system, and all amplification was performed using SYBR Green and PlatinumTaq (Thermofisher Scientific). Product quality was confirmed by melting curve analysis. The following expression primers were used: for GAPDH, forward (F) primer CATTGCCCTCAACGACCACT (SEQ ID NO: 19) and reverse (R) primer GGTGGTCCAGGGGTCTTACT (SEQ ID NO: 20); for HBB, F primer GCCCTGGCCCACAAGTATC (SEQ ID NO: 21) and R primer. For HBB, use GCCCTTCATAATATCCCCCAGTT (SEQ ID NO: 22); for HBG, use F primer GGTGACCGTTTTGGCAATCC (SEQ ID NO: 23) and R primer GTATCTGGAGGACAGGGCAC (SEQ ID NO: 24); and for EGFP, use F primer ATCTTCTTCAAGGACGACGG (SEQ ID NO: 25) and R primer GGCTGTTGTAGTTGTACTCC (SEQ ID NO: 26). Throughout this example, percentage HBG mRNA refers to the amount of expressed HBG mRNA relative to the total amount of γ-globin and β-globin transcripts ([HBG / (HBB+HBG]*100).
[0308] <Methylcellulose> As previously described, a methylcellulose colony-forming assay was performed
[12] . CD34+ cells were isolated from PBMCs using a human CD34+ MicroBeadKit (Miltenyi) and an MS column for positive selection of CD34+ cells. Isolated CD34+ cells were incubated at 37°C and 5% CO2 for 30 minutes with 200 μg / ml of CRISPR / Cas9-PLGA-NP or control NP in IMDM medium. Cells were then centrifuged and seeded on methylcellulose without washing. 500 CD34+ cells were seeded three times in 3.6 ml of methylcellulose (1 mL per dish; H4434; Stem Cell Technologies) containing 1% PS and incubated at 37°C and 5% CO2 for 14 days. Colonies were characterized, counted using a bright-field microscope, and the Cy5 signal within the colonies was obtained by scanning with a 680nm Odyssey Scanner (LI-COR, Nebraska, USA).
[0309] <Sanger sequencing and TIDE analysis> Sanger sequencing was performed on BFU-E colonies grown in methylcellulose for 14 days. After characterization and counting, BFU-E colonies were collected in 96-well plates and washed with PBS. DNA was then extracted using the Wizard Genomic DNA Purification Kit (Promega). PCR was performed using Phusion DNA polymerase (ThermoFisher Scientific) and the following primers: forward ACGGCTGACAAAAGAAGTCC (SEQ ID NO: 27) and reverse GGGTTTCTCCTCCAGCAT (SEQ ID NO: 28), with 2 μl of cell lysate as input. The PCR product was washed using Wizard SV Gel and the PCR Cleanup System (Promega). TIDE analysis was performed on Sanger sequencing trace data to access the indel frequency of BFU-E colonies using the online tool http: / / shinyapps.datacurators.nl / tide /
[17] .
[0310] <Result> <Synthesis and Characterization of CRISPR / Cas9-PLGA-NP> To avoid the efficiency and safety issues of viral vectors, PLGA-NPs encapsulating Cas9 (S. pyogenes) protein, gRNA, and the fluorescent dye Cy5 were designed (Figure 11A). The purpose of this study was to synthesize a delivery vehicle for CRISPR that could be efficiently processed in HSPCs and monitored with a fluorescence microscope. In typical solvent evaporation techniques, gRNA can easily escape from the encapsulation process due to its low molecular weight, hydrophilicity, and the electrostatic repulsive force between the phosphate backbone of RNA and the carboxylic acid end groups of PLGA building blocks
[18] . To avoid this, a previously reported method of encapsulating siRNA adsorbed on the surface of calcium phosphate into the hydrophobic core of PLGA was adapted
[13] .
[0311] Here, CRISPR / Cas9-PLGA-NP was synthesized according to the oil-in-water double emulsion solvent evaporation method (Figure 11B). Prior to encapsulation, complexes of Cy5 acid (net charge -1) and Cas9 (net charge +22) were prepared based on electrostatic interactions (Figures 11A-B). The Cy5 acid dye contains an unactivated carboxylic acid; therefore, the molecule is considered non-reactive. Instead of directly conjugating Cy5 to the Cas9 protein, forming a complex between Cas9 and Cy5 would avoid loss of Cas9 functionality and increase the encapsulation efficiency of the Cy5 dye. Next, a solution of calcium phosphate was prepared to precipitate gRNA (sgRNA or hybridized crRNA-tracer RNA complex) under the formation of a calcium phosphate / gRNA complex. In the next step, calcium phosphate-CRISPR / Cas9-PLGA-NP was synthesized; PLGA was dissolved in DCM, and then the calcium phosphate / gRNA complex in water and the Cas9 / Cy5 complex in water were added. Sonication formed the first emulsion containing the phosphate / gRNA and Cas9 / Cy5 complex in the oil phase. Addition of PVA (dissolved in water) and subsequent sonication formed a stable double oil-in-water emulsion. The organic solvent was removed under reduced pressure, and the surfactant PVA was removed by centrifugation. The resulting NP was immediately freeze-dried.
[0312] Chemically modified gRNAs were encapsulated against an enhanced green fluorescent protein (eGFP) sequence or a scrambled control sequence. Dynamic light scattering (DLS) analysis determined the NP size to be approximately 370 nm in diameter (Table 2, Figure 11D), and the polydispersity index (PDI) values of 0.1–0.2 obtained from DLS measurements showed a uniform size distribution (Table 1). In addition, ZetaSizer measurements revealed a negative surface charge of the NPs (Table 1). In contrast to control NPs without Cas9, Cas9 encapsulation increased the NP size from 215 to over 300 nm (Table 1). This indicates successful Cas9 encapsulation. Nanodrop analysis of the washing solution generated during NP synthesis showed encapsulation efficiencies of 49–75% for Cas9 and 69–89% for sgRNA. In addition, spectrophotometric measurements revealed that 26–65% of the Cy5 dye was encapsulated (Table 2).
[0313] [Table 2]
[0314] To monitor the release dynamics of Cas9 from CRISPR / Cas9-PLGA-NPs, the NPs were incubated in PBS at 37°C for 30 days, and samples were taken at specified time points. Cas9 was analyzed by nanodrop assay, and cumulative release was calculated (Figure 11E). gRNA release was calculated from batches of CRISPR / Cas9-PLGA-NPs encapsulated with Atto-550 labeled gRNA (Figure 11F). The release dynamics study showed that 30% of the encapsulated gRNA and 40% of Cas9 were rapidly released within the first 24 hours, followed by a sustained release period that continued until the end of the analysis (Figures 11E-F).
[0315] Next, the efficiency of CRISPR / Cas9-PLGA-NP uptake and gene editing was evaluated in primary human erythroblasts cultured from PBMCs using an erythrocyte differentiation protocol. In the initial stage, erythrocyte progenitor cells were grown until they dominated the cell culture around day 8. Erythrocyte progenitor cells were incubated with different concentrations of CRISPR / Cas9-PLGA-NP (encapsulating γ-globin promoter-targeted gRNA) and control NP, followed by induction of the proliferation phase. Three days after NP incubation (day 11 of erythroblast differentiation), the percentage of NP-positive cells and intracellular levels of HbF were measured by flow cytometry (Figure 12A). Similar to the results obtained in HUDEP-2 cells, NP was readily uptaken by erythroblast progenitor cells in a concentration-dependent manner (Figure 12A). 10% of primary cells expressed HbF, and despite the efficient uptake of control NP, HbF expression did not increase when incubated with control NP (Figure 12A). CRISPR / Cas9-PLGA-NP increased HbF levels to 18.1% (50 μg / ml) and 51.7% (200 μg / ml) in a concentration-dependent manner (Figure 12A). RT-PCR confirmed that HbF expression increased in a concentration-dependent manner 3 days after treatment with CRISPR / Cas9-PLGA-NP, but not in control NP (Figure 12B). Time-course analysis of HbF expression by flow cytometry showed that HbF levels further increased on days 8 and 14 after treatment with CRISPR / Cas9-PLGA-NP, while HbF levels in WT and control NP-treated cells remained constant (Figure 12C). CRISPR-Cas9-PLGA-NP at 200 μg / ml and 100 μg / ml induced high levels of HbF as early as day 3, while at 50 μg / ml, an increase in HbF levels could be detected on day 8. Genomic analysis of CRISPR / Cas9-PLGA-NP and control NP-treated erythroblasts revealed mutations in the HBG promoter region (Figure 12D). TIDE analysis was performed on Sanger sequencing trace data from the majority of edited erythroblasts to estimate the frequency and type of insertions / deletions (indels)
[17] (Figure 12E). The overall indel efficiency was 42.9%, and the majority of mutations were insertions.In summary, this data demonstrates the function and efficiency of CRISPR-Cas9-PLGA-NP in HbF induction in primary erythroblasts.
[0316] <CRISPR / Cas9-PLGA-NP-mediated gene editing of the first generation HSPC> The application of CRISPR-Cas9 technology is hindered by challenges in efficient non-viral expression and delivery of CRISPR components in CD34+ cells, particularly in HSPCs. To evaluate the efficiency of CRISPR / Cas9-PLGA-NP as a delivery system for the CRISPR-RNP complex to HSPCs, uptake studies were conducted in isolated human CD34+ cells. CD34+ cells newly isolated from PBMCs were incubated with 100 μg / ml of CRISPR / Cas9-PLGA-NP at 37°C for 1 hour, and NP binding and uptake were evaluated by confocal microscopy (Figure 14A). CRISPR / Cas9-PLGA-NP bound and was taken up by various cell types within the CD34+ cell population, including CD34high cells. Additional flow cytometry studies were conducted to analyze the binding and uptake behavior of CD34+ cells. For this purpose, CD34+ cells were incubated with CRISPR / Cas9-PLGA-NP at 4°C (where cells could bind to the NP but not take it up) and under physiological conditions at 37°C (Figure 14B). Binding and uptake of CRISPR / Cas9-PLGA-NP by CD34+ cells was concentration-dependent. Therefore, for further analysis, CD34+ cells were incubated with 200 μg / ml of CRISPR / Cas9-PLGA-NP. To evaluate the potential cytotoxicity and gene-editing capabilities of CRISPR / Cas9-PLGA-NP against CD34+ cells, clonal studies were performed on burst-forming unit erythrocyte (BFU-E) colonies derived from single cells grown in methylcellulose cultures. To avoid differentiation, CD34+ cells were incubated with 200 μg / ml of CRISPR / Cas9-PLGA-NP for a short period of time. To enhance NP loading, CRISPR / Cas9-PLGA-NPs were centrifuged with CD34+ cells, and the NP-loaded cells were directly plated onto methylcellulose. Flow cytometry confirmed the efficient binding of CRISPR / Cas9-PLGA-NPs to CD34+ cells (Figure 14C). To evaluate the number of Cy5+ colonies, the methylcellulose plates were scanned at 700 nm using the Odyssey imaging system (Figure 13).
[0317] Almost all colonies derived from CD34+ cells treated with CRISPR / Cas9-PLGA-NP were Cy5+, while WT colonies showed no background signal. Further analysis of single clones showed that almost all cells within the colonies were Cy5+ (Figure 14D). There were no differences in the number and types of hematopoietic progenitor cell colonies derived from WT, CRISPR / Cas9-PLGA-NP, and control-NP treated isolated CD34+ cells (Figure 14E). TIDE analysis of BFU-E colonies derived from CRISPR / Cas9-PLGA-NP treated and electroporated CD34+ cells revealed mutations in the γ-globin promoter region (Figure 14F). Deletions and insertions among the mutations were removed. The analyzed BFU-E colonies derived from CRISPR / Cas9-PLGA-NP treated and electroporated CD34+ cells showed on-target mutations. A mean 32% and 28% of screened BFU-E colonies derived from CRISPR / Cas9-PLGA-NP treated and electroporated CD34+ cells had indels and were mosaic for HBG1 / HBG2 mutations, respectively (Figure 14G). This most likely reflects editing over several cell divisions. RT-qPCR analysis of individual BFU-E colonies confirmed increased HbF mRNA expression in colonies derived from CD34+ cells treated with CRISPR / Cas9-PLGA-NP and electroporated (Figure 14H). Therefore, these data indicate that the functional CRISPR complex was released for an extended period in CD34+ cells, resulting in highly efficient gene editing without inducing cytotoxicity of the cells.
[0318] [References] 1.Patra et al.,"Nano based drug delivery systems: recent developments and future prospects", J Nanobiotechnology.2018;16(1):71 2.Kumari et al.,"Nanoencapsulation for drug delivery”,EXCLI J.2014;13:265-286 3.Zhao and Stenzel,"Entry of nanoparticles into cells:the importance of nanoparticle properties”,Polymer Chemistry.2018;9(3):259-272 4.Deirram et al.,"pH-Responsive Polymer Nanoparticles for Drug Delivery”,Macromol Rapid Commun.2019;40(10):e1800917 5.Hsu et al.,"Development and Applications of CRISPR-Cas9 for Genome Engineering”,Cell.2014;157(6):1262-1278 6.Brezgin et al.,"Dead Cas Systems:Types,Principles,and Applications”,Int J Mol Sci.2019;20(23):6041 7.Whinn et al.,"Nuclease dead Cas9 is a programmable roadblock for DNA replication”,Sci Rep.2019;9(1):13292 8.Wang et al.,"Identification and characterization of essential genes in the human genome”,Science.2015;350(6264):1096-101 9.Traxler, et al.,"A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition”,Nat Med.2016;22(9):987-90 10.Perez et al.,"Poly(lactic acid)-poly(ethylene glycol)nanoparticles as new carriers for the delivery of plasmid DNA”,J Control Release.2001;75(1-2):211-24 11.Luo et al.,"Controlled DNA delivery systems”,Pharm Res.1999;16(8):300-8 12.Medvinsky et al.,"Analysis and manipulation of hematopoietic progenitor and stem cells from murine embryonic tissues”,Curr Protoc Stem Cell Biol.2008;Chapter 2:Unit 2A 6 13.Dordelmann et al.,"Calcium phosphate increases the encapsulation efficiency of hydrophilic drugs(proteins,nucleic acids)into poly(d,l-lactide-co-glycolide acid)nanoparticles for intracellular delivery”,J Mater Chem.2014;B 2(41):7250-7259 14.Kurita et al.,"Establishment of immortalized human erythroid progenitor cell linesable to produce enucleated red blood cells”,PLoS One.2013;8(3):e59890 15.Ronzoni et al.,"Erythroid differentiation and maturation from peripheral CD34+ cells in liquid culture:cellular and molecular characterization”,Blood Cells Mol Dis.2008;40(2):148-55 16.van den Akker et al.,"The majority of the in vitro erythroid expansion potential resides in CD34(-)cells,outweighing the contribution of CD34(+)cells and significantly increasing the erythroblast yield from peripheral blood samples”,Haematologica.2010;95(9):1594-8 17.Brinkman et al.,"Easy quantitative assessment of genome editing by sequence trace decomposition”,Nucleic Acids Research.2014;42(22):e168 18.Cun et al.,"High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles:quality by design optimization and characterization”,Eur J Pharm Biopharm.2011;77(1):26-35 < / grna>
Claims
1. 1. An antibody conjugate comprising an antibody and a nanoparticle conjugated to the antibody, wherein the antibody targets a cell surface protein expressed on hematopoietic stem cells (HSCs), the nanoparticle comprises a gene editing payload comprising a nuclease, and the nanoparticle comprises poly(lactic-co-glycolic acid) (PLGA).
2. 2. The antibody conjugate of claim 1, wherein the nuclease is an endonuclease capable of causing single- or double-stranded breaks at specific or non-specific sites in the genome.
3. The antibody conjugate of claim 1 or 2, wherein the gene editing payload comprises one or more of a meganuclease, a zinc finger nuclease (ZFN), a transcription activator-like effector nuclease (TALEN), or a clustered regularly interspaced short palindromic repeats (CRISPR) nuclease.
4. the nuclease is a CRISPR nuclease, and optionally the gene editing payload comprises: (a) CRISPR RNA (crRNA) and trans-activated crRNA (tracrRNA), or (b) guide RNA (gRNA) The antibody conjugate of any one of claims 1 to 3, further comprising:
5. The antibody conjugate of claim 4, wherein the CRISPR nuclease is selected from CRISPR-associated protein 9 (Cas9), CRISPR-associated protein 12a (Cas12a, also known as Cpf1), CRISPR-associated protein 13 (Cas13), CRISPR-associated protein 12b (Cas12b), CRISPR-associated protein X (CasX, also known as Cas12e), CRISPR-associated protein Y (CasY), CRISPR-associated protein 14a (Cas14a), and optionally, wherein the Cas9 is SpCas9.
6. The antibody conjugate of claim 1, wherein the nanoparticles further comprise polyethylene glycol (PEG).
7. The antibody conjugate of any one of claims 1 to 6, wherein the antibody targets one of Gpr56, CD34, Gpr97, CD49, CD49f, CD90, CD117, and Endomucin.
8. The antibody targets Gpr56, and optionally the antibody comprises: HCDR1 comprising the amino acid sequence of SEQ ID NO:9, HCDR2 comprising the amino acid sequence of SEQ ID NO: 10, HCDR3 comprising the amino acid sequence of SEQ ID NO: 11, LCDR1 comprising the amino acid sequence of SEQ ID NO: 12, LCDR2 comprising the amino acid sequence of SEQ ID NO: 13, and LCDR3 comprising the amino acid sequence of SEQ ID NO: 14 Contains, or The antibody conjugate of claim 7, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 15 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
16.
9. The antibody targets CD34, and optionally the antibody comprises: HCDR1 comprising the amino acid sequence of SEQ ID NO:1, HCDR2 comprising the amino acid sequence of SEQ ID NO:2, HCDR3 comprising the amino acid sequence of SEQ ID NO:3, LCDR1 comprising the amino acid sequence of SEQ ID NO:4, LCDR2 comprising the amino acid sequence of SEQ ID NO:5, and LCDR3 comprising the amino acid sequence of SEQ ID NO:6 Contains, or The antibody conjugate of claim 7, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
8.
10. The antibody conjugate according to any one of claims 1 to 9, (i) the nanoparticles have a diameter of 150 to 400 nm, for example, 200 to 400 nm; (ii) the nanoparticles consist of a PLGA core that is surface coated with PEG; (iii) the nanoparticles are conjugated to two or more antibody molecules; (iv) the nanoparticles are conjugated to an antibody at the antibody Fc region; (v) the nanoparticles are conjugated to an antibody via a maleimide-thiol reaction; (vi) the gene editing payload is configured to edit a γ-globin locus in a genome; (vii) the gene editing payload is a CRISPR nuclease fused to one or more nuclear localization signal sequences; and / or (viii) An antibody conjugate, wherein said antibody is a heavy chain only antibody (HCAb), such as a Camelidae HCAb.
11. A pharmaceutical composition comprising an antibody conjugate described in any one of claims 1 to 10.
12. A pharmaceutical composition according to claim 11 for use in the treatment of a disease.
13. The pharmaceutical composition of claim 12, wherein the disease is a blood disease, e.g., a blood malignancy, or a hemoglobinopathy, e.g., sickle cell disease (SCD) or beta thalassemia.
14. 11. An ex vivo method for gene editing comprising administering the antibody conjugate of any one of claims 1 to 10 to a hematopoietic stem cell (HSC) population comprising cells expressing a surface antigen that is specifically bound by the antibody.
15. The method described in claim 14, wherein the gene editing payload is capable of repairing a genetic defect in HSCs.
